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At the heart of an inflammatory response lies a tightly regulated gene expression program. 
Perturbations to this finely tuned response can result in unchecked or inappropriately scaled 
inflammation, shifting the balance from protective to destructive immunity. A variety of 
post-transcriptional mechanisms play a role in the fine-tuning of an inflammatory gene 
expression program.  One such mechanism involves unproductive RNA splicing, whereby 
alternative splicing can frameshift the transcript or introduce a premature termination codon 
(PTC). These effects render the transcript nonfunctional and/or subject it to nonsense-
mediated decay.  
 
We observed such an event in Irf7, the master regulator of the type I interferon response.  We 
found a single intron was consistently retained at a level much greater than other introns in 
the Irf7 transcript.  In an effort to understand trans-acting factors that regulate this retention, 
we used RNA-antisense purification followed by mass spectrometry (RAP-MS) to identify 
the factor BUD13 as a highly enriched protein on Irf7 transcripts.  Deficiency in BUD13 was 
associated with increased retention, decreased mature Irf7 transcript and protein levels, and 
consequently a dampened type I interferon response, which compromised the ability of 
BUD13-deficient macrophages to withstand vesicular stomatitis virus (VSV) infection. 
 
Beyond this intron retention event in Irf7, we identified a variety of other unproductive 
splicing events in a number of important genes involved with the innate immune response.  
This unproductive splicing was not restricted to intron retention events.  For example, we 
identified a frequently used alternative splice site in the crucial murine antiviral response 
gene, oligoadenylate synthetase 1g (Oas1g) that led to both a frameshift and incorporation 
of a PTC.  Genome editing was used to remove the alternative splice site in a macrophage 
cell line, which led to both increased Oas1g expression and improved viral clearance.  We 
hypothesize these events exist as a means of mitigation for what might otherwise be an 
inappropriately scaled response.  In doing so, they represent a previously underappreciated 
layer of gene expression regulation in innate immunity.   
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mRNA Splicing and Post-Transcriptional Regulation 
While transcription is the most well-scrutinized area of gene expression regulation1,2, there 
have emerged a variety of post-transcriptional mechanisms that play a role in the fine-tuning 
of a gene expression program (Figure 1.1).  These post-transcriptional mechanisms act in 
concert to ensure proper expression of individual transcripts given the cell-type and 
environment.  In general, such regulation involves the alteration of either lifespan, 
localization, or translational efficiency of a given RNA molecule.  In doing so, a cell can 
effectively adjust at the post-transcriptional level how many functional gene products are 
produced during a given period of time. 
 
Figure 1.1: Common mechanisms of post-transcriptional gene expression regulation. (Adapted from 
ruo.mbl.co) 
 
One mechanism that in recent years has emerged as an important mediator of post-
transcriptional gene expression regulation is RNA splicing.  The vast majority of human 
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genes contain multiple exons, with adjoining intronic sequences that need to be spliced from 
a transcribed pre-mRNA to form the mature mRNA.  Through a process known as alternative 
splicing (AS) a single pre-mRNA can be variably spliced into unique mature transcripts.  The 
advent of next generation sequencing has led to a wealth of transcriptomic data over the past 
decade.  This, coupled with the development of computational tools that allow proper 
analysis of splicing events (Box 1), has shed light on the widespread nature of AS.  This 
process is extensively controlled in different tissues, cell types, and differentiation stages3–8, 
and dysregulation is believed to be significantly contribute to the development of human9,10 
disease11–13.    
Despite the fact most mammalian genes exhibit alternative splicing14,15, not all of the 
produced transcripts encode functional proteins (Figure 1.2).  In cases where translation does 
occur, different splice variants can lead to different protein functions.  However, in addition 
to these cases, which we define as productive splicing events, AS can also generate 
unproductive isoforms that are not translated and are either subjected to decay or have their 
expression restricted to the nucleus16.  Starting with the latter, this chapter will cover RNA 
splicing as a mechanism of post-transcriptional gene expression and further, discuss the 
relevance such regulation has with respect to human physiology and disease. 
Unproductive alternative splicing 
While its evident alternative splicing in certain cases acts to increase proteomic diversity, it 
can also generate isoforms that either shift the frame of the transcript, altering the coding 
region in the process, and/or lead to the incorporation of a premature termination codon 
(PTC).  The vast majority of these isoforms are subjected to decay17,18, primarily by the 
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Nonsense-Mediated Decay (NMD) pathway19 in the case of PTC-containing transcripts.  
However, there exists a nuclear exosome, which is responsible for degradation of unspliced 
RNAs in the nucleus20,21.  In essence, by preventing the production of the final gene product, 
these events allow a cell to functionally down-regulate expression of a given gene at the post-
transcriptional level.  This mechanism of regulation has been called AS coupled to NMD 
(AS-NMD) or Regulated Unproductive Splicing and Translation (RUST)22, the latter being 
the term we will use to broadly describe all unproductive splicing events (with the exception 
of the fourth chapter, where the term AS-NMD is used due to likely degradation of Oas1g 
transcripts by the NMD machinery).  It has been estimated between 10-30% of mammalian 
genes may be regulated post-transcriptionally through RUST, potentially in a context specific 
manner, through unproductive splicing17,18,23,24. 
 
Figure 1.2. A schematic depiction of constitutive splicing as well as the different forms of alternative 
splicing.  Depicted on the left are the pre-mRNA with the possible splice choices represented.  
Depicted on the right are the possible mature mRNA isoforms from each alternative splicing event.  
The stop sign represents the inclusion of a premature termination codon (PTC), which thus subjects 
the transcript to decay. 
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The coupling of alternative splicing to decay has been shown to affect a variety of 
biological processes.  Perhaps most well studied are the consequences of RUST in the 
autoregulation of splicing factor genes.  Initially discovered to impact the autoregulation of 
serine/arginine-rich (SR) proteins in C. elegans25, RUST is now recognized as a wide-spread 
mechanisms of splicing factor autoregulation24,26–30.  With respect to SR protein 
autoregulation, this occurs through the establishment of a negative feed-back loop.  SR 
proteins bind to cis elements of a pre-mRNA molecule and can promote the inclusion of an 
exon at a nearby junction31.  An increase concentration of a given SR protein can lead to the 
inclusion of a cassette exon in its own transcript, which contains a PTC and thus subjects the 
transcript to NMD decay (Figure 1.3).  Such exons are termed poison cassette exon32.  This 
leads to less production of the SR protein, in turn reducing the inclusion of the poison cassette 
exon.  In addition to autoregulation, cross-regulation can occur where RUST is used to 
regulate the expression of other splice factors, exemplified by the negative regulation of 
PTBP2 by PTBP133.  However, the impact of RUST extends beyond splicing factor 
regulation.  More recently, RUST has been implicated in the regulation of transcripts that 
play a role in cellular differentiation4–6,34–36, chromatin modification37, and inflammation7,38.   
 
Figure 1.3. Schematic depiction of auto-regulatory negative feedback.  The coded splicing factor 
promotes the inclusion of a poison cassette exon, thus regulating its own NMD event.  When levels of 
the splicing factor are high, the unproductive transcript incorporating the poison cassette is 
frequently used, leading to a reduction in splicing factor production.  When levels of the splicing 
factor are low, the productive transcript is frequently used, leading to an increase in splicing factor 




In the last decade, with respect to unproductive splicing, IR has emerged as a 
previously underappreciated form of AS that mediates post-transcriptional gene expression 
regulation.  The transient nature of an intron, as well as transcripts that retain introns due to 
swift degradation, has made it hard to identify and quantify retention39.  However, 
improvements in next-generation sequencing have played a large role in changing this.  
While there are cases of IR containing transcripts being translated40–42, the vast majority of 
these isoforms are subjected to decay17,18 either via the NMD pathway19 or the nuclear 
exosome20,21.  Thus, as was the case for RUST mediated by other AS events, IR can 
functionally “tune” the transcriptome of a cell43.  IR as a mechanism of gene expression 
regulation is maybe best exemplified through the study of cellular differentiation.  One 
notable study involved the impact of IR events on granulopoiesis5.  As a granulocyte 
develops from a promyelocyte, IR is found to be dramatically upregulated in a subset of 
junctions, ultimately leading to a decrease in the corresponding proteins expression.  
Accompanying this IR is the downregulation of a number of important spliceosome and 
splicing factor genes.  Many of these IR events are found in genes coding for proteins that 
play an important role in nuclear structure, an interesting finding considering granulocytes 
have a multi-lobed, highly deformable nuclear morphology which allows them to move 
through tissue interstitial spaces44.  One particular example involved LaminB1 (Lmnb1), 
whereby retention in a number of introns in the transcript was upregulated >100-fold and 
mRNA expression was down-regulated 100-fold.  Expression of intronless Lmnb1 reduced 
granulocyte numbers and altered nuclear morphology.  Thus, it was concluded that 
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orchestrated IR coupled with degradation could act as a physiological mechanism of gene 
expression control, ultimately affecting an important cellular differentiation pathway. 
In contrast to regulation via degradation, a scenario where these IR events are spliced 
in a delayed or regulated manner is also possible.  For example, in LPS induced macrophages, 
certain introns were found to represent rate-limiting intermediates, thus acting as a timing 
mechanism altering the kinetics of gene expression38,45–47.  Another scenario involves a group 
of introns that have been defined as “detained introns” (DIs)48.  Such introns are defined as 
being unspliced in otherwise fully spliced polyadenylated transcripts, which in turn leads to 
nuclear retention of the transcript44,48.  While it is possible some degradation occurs in the 
nucleus via the nuclear exosome, these transcripts are insensitive to NMD due to their nuclear 
localization.  Regardless, they negatively regulate protein expression as they are not 
translated. This negative regulation can be removed through post-transcriptional splicing, 
which has been shown to occur in response to certain stimuli4,34,48,49.  Alteration of DI 
splicing can have major physiological consequences.  It was recently shown that in 
glioblastomas (GBM), the arginine methyltransferase PRMT5, upregulated in high grade 
gliomas50,51, regulates the splicing of detained introns through the modulation of snRNP 
biogenesis49. Inhibition of PRMT5 had an antitumor effect, believed to be mediated through 
an increase in DIs.  Many of these DIs were located in genes that were predominantly 
associated with proliferation and neurogenesis. It was concluded that GBMs, through 
PRMT5, assume control of DI splicing allowing them to upregulate a gene expression 
program suited for proliferation.  With respect to slow-splicing junctions and DIs, a great 
deal of work is needed to understand the exact nature of such junctions, to determine the 
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extent to which they are post-transcriptionally spliced as compared to degraded, and to 
understand the factors that regulate them.  
 
Other forms of AS mediated post-transcriptional regulation. 
In contrast to unproductive AS events, productive AS events do not shift the frame of the 
transcript and/or lead to the incorporation of a premature termination codon (PTC).  As such, 
the resulting isoforms have the potential to be translated into functional protein products.  
Still, these AS events have the ability to affect post-transcriptional regulation.  Productive 
AS can lead to a protein product that has an altered function.  In many cases, this new function 
is not consistent with the original function, or even further acts to negatively regulate the 
original function.  This form of regulation is particularly ubiquitous in the innate immune 
response52–60.  For example, there exists an alternative splice variant of the toll-receptor gene 
Tlr4 that introduces an extra exon that contains an in-frame stop codon52.  Tlr4 is a pattern 
recognition receptor (PRR) that is most well-known for recognizing the Gram-negative 
bacteria component lipopolysaccharide, leading to activation of an innate immune 
response61.  This in-frame stop codon leads to the generation of a soluble form of TLR4 that 
still binds LPS, but no longer has the ability to signal to downstream components.  Thus, it 
acts to negatively regulate a Tlr4 response.  Interestingly, many of the AS events that lead to 
negative regulation of the original protein product in the innate immune response are induced 
by LPS stimulation, suggesting that such negative regulation is needed to ensure responses 
are self-limiting52,53,60,62.  
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Beyond these AS events that lead to productive transcripts, AS in non-coding regions 
of a transcript can have a major effect on the stability of a transcript.  One such case involves 
the regulation of transcript stability through AS at junctions located in the 3’ UTR63.  The 3’ 
UTR is an important determinant of transcript stability.  Both miRNAs and RNA binding 
proteins can bind to the 3’ UTR and alter transcript stability.  With respect to miRNAs, 
binding at the 3’ UTR negatively regulates gene expression64.  However, in order for this 
regulation to occur, the miRNA binding site must be present in the transcript.  It has been 
estimated that one third of miRNA binding sites are controlled by AS events65.  This is 
exemplified by a case involving the divalent metal transporter 1 gene (DMT1), which 
contains two alternative 3’ terminal exons66.  One isoform contains an iron response element 
(IRE), the other does not.  The isoform lacking this IRE carries a binding site for the miRNA 
let-7d, which in turn limits expression of this isoform but has no effect on the isoform 
containing the IRE.  Down-regulation of let-7d during erythroid differentiation allows the 
DMT1 isoform without the IRE element to become more prevalent.  While the 3’ UTR plays 
an important role in transcript stability via miRNA regulation, it also has an effect on 
transcript stability due to binding of RNA-binding proteins (RBPs) to the region.  A notable 
example of this type of regulation involves 3′UTR-enriched AU-rich elements (AREs) that 
recruit corresponding RBPs67–70 and modulate transcript stability and translational activity63.  
As was the case with miRNA regulation, ARE mediate regulation can be affected by AS71.  
For example, in the human parathyroid hormone-related protein (PTHrP), three alternative 




More recently, work in S. cerevisiae has identified a new mechanism by which an 
AS event can post-transcriptionally regulate a gene expression program.  A new class of 
“spliceosome-sequestering” introns were found to play a key role in the cellular response of 
S. cerevisiae to nutrient deprivation73,74.  These introns are either retained, forming a hairpin 
with the 5’ UTR73, or they are first excised and then stabilized through interactions with 
spliceosomal proteins74.  Then, under stress, these introns modulate splicing by sequestering 
specific spliceosome components.  In the case of S. cerevisiae cells under nutrient 
deprivation, this modulation of splicing leads to dampen the expression of highly expressed 
genes as a means of energy conservation during starvation.75  It will be interesting to see if a 
similar mechanism of gene expression regulation occurs in both higher eukaryotes and other 
physiological conditions.  
 
Regulation of AS Events 
While a large body of work has identified and classified a number of the AS events that 
mediated post-transcriptional regulation, it remains unknown the extent to which these events 
are actively regulated by an external input.  A simpler scenario involves transcripts being 
split between isoforms at a constant ratio.  As such, the combined effect of the AS on a gene 
expression program remains relatively constant.  For example, in cases of unproductive 
splicing where AS is coupled with NMD, the reduction of mRNA abundance occurs by a 
relatively constant factor.  There are a number of examples of such events, including in the 
widely expressed protease Calpain-10 which has four isoforms that incorporate PTCs and 
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have shown to be consistently downregulated76,77. However, in all of these situations, such a 
conclusion is quite difficult to make due to the potential for undiscovered regulatory inputs.  
Contrary to constitutive unproductive splicing, it is also possible for external factors 
to regulate splicing mediated post-transcriptional gene expression regulation.  For example, 
a change in the abundance of splicing factors can promote the production of an unproductive 
splicing event.  This in turn will reduce the number of transcripts and the amount of 
functional protein products.  This is exactly what happens in the aforementioned work 
involving orchestrated IR during granulocyte differentiation as the observed IR is 
accompanied by downregulation of spliceosomal components and trans-acting splicing 
factors5.  In contrast, the factors that regulate other seemingly orchestrated AS events that 
occur in response to a given stimuli remain poorly understood.  During an innate immune 
response, there is a significant increase in isoform diversity78.  While some factors have been 
identified that play a role in either “safe-guarding” proper splicing or regulating a given AS 
event7,62,79, it remains unknown why the majority of these AS events occur in the presence 
but not absence of stimulation.  This is epitomized by the aforementioned case with Tlr4.  It 
is possible that some of this increase in AS is due to burden on the spliceosome, akin to what 
is seen upon oncogenic MYC activation80.  Stimulation leads to an orchestrated 
transcriptional response which in turn increases the amount of RNA that needs to be spliced.  
Regardless, new RNA centric methods have been developed that allow for the discovery of 
RNA/protein interactions.  Methods like RAP-MS81 and ChIRP82, promise to help identify 
trans-acting factors that regulate these AS events and thus, contribute to post-transcriptional 
gene expression regulation.  In fact, the third chapter of this thesis describes use of RAP-MS 
to discover an RNA-protein interaction that aids in the splicing efficiency of an IR event in 
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Irf77.   This protein, BUD13, was found to be enriched on Irf7 transcripts using RAP-MS, 
and deficiency of BUD13 led to increased IR in Irf7.  This increased IR was associated with 
impaired induction, a dampened type I interferon response, and consequently an inability to 
clear virus.  As these methods continue to improve, our understanding of external regulation 
of AS events affecting gene expression should continue to blossom.   
 
Conclusion 
Advancements in next-generation sequencing technologies have drastically improved our 
understanding of AS.  This in turn has led to the development of AS as a mechanism of gene 
expression regulation.  Increased wealth of transcriptomic data from a wider variety of cell-
types and more physiological conditions promises to further improve our understanding of 
such regulation.  Further, seeing as dysregulated AS has been shown to be widespread in a 
variety of diseases, from cancer to autoimmunity, our understanding of AS mediated gene 
expression regulation could shed light on the relationship between alterations in isoform 
abundance and disease pathogenesis13,83–86.   
Inherently, regulation at the post-transcriptional level might seem inefficient.  Why 
spend the resources to transcribe a transcript if it is destined for degradation?  First and 
foremost, the very fact introns exist and are transient in nature argues against the idea that 
the cost of transcription is prohibitive22.  A significant majority of transcribed sequence 
(~90% in humans87) is spliced and discarded. As such, it can be argued the fine-tuning 
capabilities inherent to splicing based post-transcriptional regulation far outweigh the 
cellular cost of additional transcription.  Additionally, it is well understood that 
transcriptional regulation is largely a cooperative venture88, epitomized by complexes like 
  
13 
the interferon-β (IFN-β) enhanceosome89.  As transcriptional regulation is not simply one 
protein interacting with one DNA sequence, but instead a multitude of proteins interacting 
with a host of other proteins and a variety of DNA sequences, it is quite possible that once 
transcriptional control has been placed on a system, changing it quantitatively is difficult.  
Thus, secondary mechanisms, like mRNA splicing, are needed to fine-tune the gene 
















Box 1 – Computational Analysis of RNA Splicing 
There are a number of widely used computational tools designed to analyze and quantify 
differential splicing in RNA-seq data.  Broadly, they fall into two main categories.  The 
first category involves tools that utilize a transcript-based approach, whereby an 
expectation-maximization algorithm is used to estimate isoform abundance90,91.  Recent 
progress in pseudo-alignment has allowed for the development of tools like kallisto92 and 
Salmon93, which perform alignment free isoform quantification and are computationally 
extraordinarily efficient.  Still, the identification and quantification of full-length 
transcripts from short reads is non-trivial and further, in the case of pseudo-alignment, the 
approach is inherently sensitive to the input transcript annotations (i.e. an input recording 
the precise location of intron and exon boundaries), which may be incomplete or 
inconsistent94,95.   
The second category involves tools that utilize an event-based approach.  These 
tools ignore the estimation of isoform expression and instead, detect alternative splicing 
events by comparing reads at a given junction between multiple samples and quantifies 
using a metric like percent spliced in (PSI/Ψ).  There are a variety of commonly used tools 
in this category (i.e. MISO96, rMATS97, MAJIQ98, Leafcutter99, SplAdder100, JUM101 and 
Whippet102).  Each has its own intricacies, most notably the statistical methods used to 
quantify differences between data-sets and the extent to which they rely on a pre-annotation 
of known alternative splicing events.  The latter can alter the number of events detected as 
programs that can augment an annotation or are annotation free are inherently able to detect 
a wider range of alternative splicing events.  However, for a given set of alternative splicing 
events, the tools produce very similar PSI values95.    
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Overview of thesis 
The overarching theme behind this thesis is the study of RNA splicing as a means of post-
transcriptional gene expression regulation.  In particular, this work focuses on how splicing-
mediated post-transcriptional regulation affects an inflammatory response.  Central to an 
inflammatory response is a robust and coordinated gene expression program.  Tight 
regulation of this gene expression program is essential as small alterations can shift the 
balance from protective to destructive immunity.  While transcriptional control certainly 
drives such a regulated gene expression program, post-transcriptional regulation has been 
shown to be essential to aid in the fine-tuning of expression.  Inherently, post-transcriptional 
regulation appears inefficient.  Why transcribe a transcript simply to throw it away?  But as 
will be discussed, transcriptional regulation is largely a cooperative venture, involving a host 
of proteins and a range of cis elements.  Thus, secondary mechanisms are needed to fine-
tune the gene expression levels of select transcripts.  The benefit of quickly fine-tuning 
expression of select transcripts post-transcriptionally far outweigh the cellular cost of 
additional transcription, especially in the context of a tightly regulated gene expression 
program like inflammation. 
The first chapter will present background information with respect to mRNA splicing 
and its ability to mediate post-transcriptional regulation, particularly in the fine-tuning of an 
inflammatory response.  Chapter 2 will cover our work quantifying the rates of intron splicing 
throughout the NF-κB transcriptome, and our identification of intron retention events that 
remain extraordinarily unspliced throughout a stimulation time-course.  In Chapter 3, we 
focus on one such retention event in Irf7, the master regulator of the type I interferon 
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response, and attempt to find trans-acting factors that regulate the level of retention.  Using 
RNA Antisense Purification followed by Mass Spectrometry (RAP-MS), we identified the 
RNA binding protein BUD13 as enriched on Irf7, and further perform Bud13 knockdown 
studies to show altered Irf7 induction and an impaired anti-viral response in macrophages 
deficient of Bud13.  Chapter 4 expands our study of splicing as a post-transcriptional 
mechanisms of gene expression regulation during inflammation by focusing on alternative 
splicing events beyond intron retention.  While it is true that alternative splicing (AS) can act 
to increase proteomic diversity, it can also generate unproductive isoforms that incorporate 
a premature termination codon (PTC), and are thus subjected to NMD or exosomal decay.  
We focus on one frequently used unproductive splicing event in oligoadenylate synthetase 
1g (Oas1g), an important murine anti-viral response factor, and show that removal of the 
alternative splice site mediating this AS event increases expression of Oas1g and 
consequently, improves the ability for macrophages to clear viruses.  Finally, Chapter 5 
concludes this thesis by offering insight regarding the future directions and potential 
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The process of inflammation involves a coordinated gene expression program.  Tight 
regulation of this gene expression program is crucial to ensure inflammation remains 
properly scaled.  Here, we developed a RNA “hybrid-capture” purification technique to 
enrich for specific cDNAs relevant to the NF-κB pathway, which thus allowed us to 
investigate the role of pre-mRNA splicing in the regulation of inflammatory gene expression.  
Our results support the notion that most introns in mRNA are spliced linearly and co-
transcriptionally (i.e. the earlier an intron is transcribed, the earlier it will be spliced).  
However, a number of transcripts contain introns that are spliced at significantly slower rates 
than neighboring introns. In many instances, poor splicing at such junctions is attributable to 
evolutionarily conserved poor splice donor sequences.  This has led to the idea that specific 
introns, so called “bottleneck” introns, can regulate the expression of genes through the 











Essential to an effective inflammatory response is a tightly regulated gene expression 
program.  Small alterations to this program can shift the balance from protective to 
destructive immunity1.  While transcription and protein turnover are the most well-
scrutinized area of gene expression regulation2–5, there have emerged a variety of post-
transcriptional mechanisms that play a role in the fine-tuning of an inflammatory gene 
expression program i.e. RNA stabilization6, RNA deadenylation7, and microRNA 
regulation8.  We and others have recently investigated the role of RNA splicing as a means 
of post-transcriptional gene expression regulation9–13.   
RNA synthesis begins with the initiation of transcription by RNA Polymerase II (Pol 
II) at the promoter region of a gene.  Pol II synthesizes RNA as it elongates through the DNA 
template until transcription is terminated many kilobases downstream14.  This pre-mRNA 
contains many intervening sequences (introns) that are excised allowing the remaining 
sequences (exons) to be concatenated together to form a mature eukaryotic RNA transcript15.  
Following the completion of transcription, pre-mRNA molecules must be cleaved from the 
template DNA and polyadenylated at the 3’ end16.  Then, full-length completely spliced 
transcripts can be released into the cytoplasm. In cases where a transcript retains an intron, 
such a transcript can remain in the nucleus and undergo delayed splicing17, or be degraded 
via the nuclear exosome or the NMD decay machinery in the cytoplasm18.  This allows a cell 
to fine-tune when and how much message is produced at the post-transcriptional level.  While 
there are exceptions, it is rare for a transcript with a retained intron to contribute to proteomic 
diversity19.   
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In order to understand the role of splicing with respect to the timing and levels of 
gene expression during an inflammatory response, a proper analysis of the rate of pre-mRNA 
processing is needed.  Current methods, namely qPCR and RNA-seq, have limitations with 
respect to such analyses.  qPCR is inherently limited by the number of junctions with which 
can be analyzed, and because of the relative number of transcripts involved with the 
inflammatory response as compared to total mRNA, RNA-seq results in limited resolution 
at the majority of induced junctions.  To overcome this sequencing depth problem, we 
developed a RNA “hybrid-capture” purification technique to enrich for specific cDNAs 
relevant to the NF-κB pathway, which thus allowed us to investigate the role of pre-mRNA 
splicing in the regulation of inflammatory gene expression.  We found that the majority of 
splicing is co-transcriptional.  However, there were junctions in important inflammatory 
transcripts that were significant outliers, remaining primarily unspliced throughout a 
stimulation time-course.  We hypothesize that these outliers, which we deem “bottleneck” 
introns, regulate the timing and levels expression of their respective genes through the delay 
of splicing and decay of intron containing transcripts.   
Results 
Hybrid-Capture Optimization 
The first step in the project involved implementing the “hybrid-capture” purification 
technique (Figure 1A)20.  This technique utilizes biotinylated 120-nucleotide sense strand 
probes that are able to form strong hybrids with the target, antisense cDNA.  These probe-
DNA complexes are captured with streptavidin-coated beads and then undergo multiple 
washes before the captured sequences are eluted into a basic solution.  Probes were designed 
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that were targeted to the last exon of all of the  >300 genes in the NF-κB transcriptome 
previously shown to be highly induced by an LPS immune response in macrophages10.  
Oligo(dT) priming and the choice of the last exon as a capture target enabled us to sequence 
complete transcripts from the standpoint of the splicing machinery, because all introns will 
have been transcribed in such transcripts.  To ensure efficient pull-down of targeted genes 
120bp probes were created that were tiled to sequences form the last exons of transcripts 
using a process called microarray printing.  The oligonucleotides for each fragment were 
synthesized via microarray printing, a T7 promoter was appended through the use of PCR, 
and biotinylated RNAs were made with an RNA Pol reaction from the PCR product.  qPCR 
was used to measure efficiency of “pull-down”, which showed significant enrichment for 
targeted transcripts and correspondingly, depletion of the non-targeted transcript RPL32 
(Figure 1B-D).   
Upon optimization of the “hybrid-capture” protocol, our next goal was to optimize 
the library preparation protocol in order to be able to submit the samples for initial Illumina 
sequencing.  In a typical library preparation for Illumina RNA-Seq, samples are reverse 
transcribed and sheared to ~200 bp.  Then, samples are end-repaired and dA-tailed to allow 
for the ligation of a specific Illumina adaptor.  These adaptors allow for further non-biased 
amplification via PCR and are necessary for sample bridge formation on flow cell, an 
essential component of Illumina’s sequencing by synthesis (SBS) approach.  Despite the 
optimization we performed on the hybrid-capture, the technique is only able to effectively 
“pull-down” a limited number of transcripts.  This presents a number of issues with respect 
to sequencing library preparation as a typical Illumina library preparation protocol requires 
>1ng of input DNA.  As we capture much less than 1ng, we needed to develop a way to 
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amplify these “pulled-down” transcripts in a manner that introduces no length or sequence 
biases. The molecular biology to do this successfully involves investigation and feasibility 
studies of several methods of Rapid Amplification of cDNA Ends (RACE).   
Our initial approach utilized T4 RNA ligase to perform a single-stranded ligation 
that adds a specialized adaptor sequence onto samples.  As the samples had been reverse 
transcribed with a special 5’ poly-A primer that contained a unique flanking handle, the 
ligation of the second handle to the 3’ end of the samples would allow for non-biased whole 
sample PCR enrichment.  Two PCR primers specific for the 5’ and 3’ handles could be 
designed to amplify the entire sample.  At the extremely low concentration of DNA that 
we were working with, this ligation proved to be problematic.  Our analysis showed that 
there was only a 0.01% alignment between our reads and the reference genome.  Further 
inspection of the sequencing reads showed a plethora of reads that contained the sequence 
of the adaptor that was used in the T4 RNA ligase reaction.  We concluded that the 
extremely low concentration of the sample hindered the efficiency of the ligation reaction, 
in turn preventing us from amplifying our sample. 
Next, we tried to use terminal deoxynucleotidyl transferase (TdT) to add the 3’ 
handle to the captured DNA sample.  TdT is a template independent polymerase that is 
able to add specific deoxynucleotides to the 3’ end of DNA molecules21.  TdT plays an 
important role in V(D)J recombination as it is able to add N-nucleotides during antibody 
gene recombination, allowing for junctional diversity21.  We attempted to first add a poly-
cytosine handle by adding TdT and a specific concentration of deoxycytidine triphosphate 
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(dCTP). At 2.5 uM, a ~5-25 cytosine handle was shown to be added.  However, the 
subsequent PCR amplification reaction involving the complementary poly-guanine PCR 
primer proved to be extremely inefficient.  Attempts made using different nucleotide base 
handles and PCR primer combinations had similar amplification issues.  
Finally, our last attempt at RACE exploited the ability of MMLV reverse 
transcriptase to “template switch”.  Prior to the hybrid capture, the extracted RNA needs to 
be reverse transcribed to cDNA.  Because the MMLV reverse transcriptase enzyme has 
terminal transferase activity22, when it reaches the 5’ end of an RNA molecule, it adds a few 
additional nucleotides (primarily deoxycytidine).  A special “template-switch” 
oligonucleotide that contains a poly(G) sequence at its 3’ end is simultaneously added to the 
reverse transcription reaction.  The 3’ end of this oligonucleotide base pairs with the 
deoxycytidine stretch that the MMLV reverse transcriptase added to the synthesized cDNA.  
Reverse transcriptase then is able to switch template, adding the complementary sequence to 
the “template switch” oligonucleotide to the end of the synthesized cDNA molecule.  This 
“template switch” method of RACE provides the second handle needed for the non-biased 
amplification.  We tested the method by performing the “template switch” reverse 
transcription on RNA from LPS stimulated bone-marrow derived macrophages (BMDMs). 
Initial libraries showed read alignments >70% (data not shown).  Comparison of the “hybrid-
capture” derived sequencing data to data from LPS stimulated BMDMs that had not been 
captured10 highlights the effectiveness of the capture.  Counting reads that map to NF-κB 
transcriptome (i.e. reads of interesting transcripts induced by LPS stimulation), ~70% of the 
reads from the capture data set map to the transcriptome as compared to ~2% of the reads 
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from the non-capture data-set (Figure 2A-C).  This makes our protocol more cost-efficient, 
as greater depth can be achieved for transcripts of interest without an increase in the total 
number of reads sequenced.  
Splicing Analysis 
Following optimization, chromatin-associated captured transcripts from BMDMs induced 
with TNFα were sequenced.  To quantify splicing, we modified we modified what is known 
as the Completed Splicing Index (CoSI) that was originally published as a part of the 2012 
ENCODE project23. The CoSI metric from the ENCODE project offers insight into the 
splicing of introns around a single exon (i.e. the extent of splicing of the introns upstream 
and downstream of a given exon).  As we wanted to narrow in on intron specific splicing, we 
modified this CoSI value so that it would only provide us with a ratio for the extent of splicing 
around a single intron (Figure 3A).  CoSI values of 1 and 0 imply near-complete splicing and 
virtually unspliced states, respectively.  Using the CoSI metric, quick induction of IκBα can 
be seen by the significant drop in the CoSI values within the first 5 minutes of TNFα 
stimulation (Figure 3B).  This drop corresponds to active transcription of IκBα.  Further, this 
CoSI data again supports the conclusion that splicing occurs primarily co-transcriptionally.  
The closer an intron is to the 3’ end of the transcript, the lower its CoSI value and thus, the 
less likely it is to be completed splicing upon completion of transcription.  Strikingly, the 
final intron deviates significantly in its kinetic trajectory, as its read density does not obey a 
similar relative reduction. This might be due to a lag in terminal intron splicing24 or a feature 
of splicing that accompanies transcript release from chromatin.   A global analysis of CoSI 
data using a single time point (12 minutes) from the TNFα stimulation time course showed 
  
33 
this statement more conclusively.  Introns were grouped based on their location to the 3’ end 
of their respective transcripts.  From these groups, we calculated the average CoSI values.  
As shown in Figure 3C, terminal (3’) introns have lower CoSI values on average than 5’ 
introns.  This agrees with a recently published co-transcriptional splicing model developed 
by the Hoffmann lab at UCLA25.  Hoffmann models splicing as a series of sequential 
reactions where the time of each reaction is an independent, exponentially distributed random 
variable (with an associated rate constant).  In turn, the probability that an intron has been 
spliced at a certain time is dependent only on the time following synthesis of the intron and 
the rate at which the intron is spliced. Assuming similarity in the rates of splicing between 
introns, an assumption which will later be shown to not always be valid, this model predicts 
terminal introns will have much lower co-transcriptional splicing efficiencies as they are 
synthesized last and thus, there is less time between synthesis and completion of transcription 
/ polyadenylation.   
We next used the CoSI metric to study splicing on a global scale across all time 
points.  Figure 4A represents the CoSI values in Tukey boxplot format for all introns in the 
NF-κB transcriptome at different TNFα stimulation time points.   The majority of introns 
splice relatively quickly and consistently.  Their CoSI values dip with the initiation of 
transcription following stimulation; however, the introns transcribed during this induction 
phase are spliced out and the CoSI values return to their non-stimulated levels in well under 
60 minutes.  In saying this, there are numerous splicing outliers that reveal delayed 
inflammatory introns.  In particular, the fourth intron of IRF7, shown in Figure 4B, 
epitomizes a delayed intron that is spliced at a much slower rate than would be expected and 
can be seen as an outlier on the plot.  IRF7 is one of many genes among our list of NF-κB 
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induced genes that have an intron that splice with notably slow kinetics.  Other inflammatory 
genes with a conspicuously and consistently unspliced intron include: CD40 (Figure 5A), 
DAXX (Figure 5B), A20, CXCL2, BAX, IκBɛ, IL27, DUSP2, MX1, XBP1, and CD79a.  
We hypothesize that the timing of expression of certain of these genes may represent a 
biological mechanism delaying or limiting their expression and that regulation of intron 
splicing may be an important avenue in understanding the processes limiting inflammation. 
Thus, we have given them the name “bottleneck” introns as they presumably prevent the 
completion of the full-length spliced transcript well past the completion of transcription.  It 
is interesting to note that many of these “bottleneck introns” contain evolutionarily conserved 
splice donors or acceptors that differ from the consensus donor/acceptor sequences.  Figure 
6 depicts the case for the poorly spliced fourth intron of IL27, which has a splice donor that 
both differs from the consensus sequence and is conserved across a variety of species.   We 
hypothesize that this non-consensus, “poor” splice donor plays a role in the regulation of 
expression of the IL27 gene, thus the reason it is evolutionarily conserved.  
Next, we measured the rates of splicing across the transcriptome.  As ongoing 
transcription complicates the process of quantitatively analyzing splicing rates and intron 
half-lives, we decided to again stimulate BMDMs with TNFα but halt transcription using 
actinomycin D (ActD) to get at meaningful quantification of the splicing pattern.  ActD is 
able to stop transcription by binding DNA at the transcription initiation complex and 
preventing the elongation of the RNA chain by RNA polymerase26.  Once transcription is 
stopped, it becomes feasible to accurately measure the rate of intron disappearance.  BMDMs 
were first stimulated with TNFα and then, 8 minutes after stimulation, were treated with 
ActD.  Whole cell RNA was enriched for mRNAs from the NF-κB transcriptome and 
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sequenced.  Whole cell RNA was used as opposed to chromatin-fractioned RNA to prevent 
biasing for introns in transcripts and thus, artificially increasing their half-lives.  Figure 7A 
shows the IκBα sequencing reads for our TNFα / ActD time course.  Following the addition 
of ActD, intron levels rapidly decreased indicating splicing without simultaneous 
transcription.  To quantify intron half-lives, we performed an exponential fit of the CoSI data 
following the addition of the ActD (Figure 7B, C).  Then, by using the fit to determine the 
time it takes for half the intron to disappear (in other words, the time it takes for the CoSI 
value to get to the midpoint of its maximally unspliced and maximally spliced levels), we 
could quantify the rate with which each intron was being spliced.  The majority of introns 
had relatively small (<250 seconds) half-lives (Figure 7B), indicating the efficiency with 
which they were being spliced.  However, there was a great deal of heterogeneity in these 
half-life values. The distribution of half-lives for introns in the NF-κB transcriptome ranged 
from 30s to 10 minutes. 
Finally, we looked at the correlation between splicing rates and transcriptional gene 
expression groups.  Previous work by the Smale group at UCLA used RNA-Seq transcript 
expression levels to group genes in the NF-κB transcriptome as either early, intermediate, or 
late induced (Figure 8). With our TNFα stimulation time course data, we used Tukey 
boxplots to globally represent the CoSI values for the introns within each of these groupings 
(Figure 8A).  As seen in Figure 8A, we are able to show that early genes tend to splice quicker 
than intermediate genes, which tend to splice quicker than late genes.  Although there are 
outliers, the mean and the 25th percentile or the lower edge of the IQR box shifts lower the 
later the expression of the grouping.   This result naturally fits with a hypothesis whereby the 
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rate at which introns of given transcript splice have the ability to effectively regulate the 
timing of the expression of a given gene.   
Discussion 
In this study, we sought to investigate the role of pre-mRNA splicing in the regulation of 
inflammatory gene expression.  We developed a “hybrid-capture” method which allowed us 
to enrich for transcripts in the NF-κB transcriptome.  We found that the majority of junctions 
splice efficiently.  Further, the closer an intron is to the 3’ end of the transcript, the lower its 
CoSI value and thus, the less likely it is to be completed splicing upon completion of 
transcription, agreeing with a largely co-transcriptional model of splicing23,27,28.  In saying 
this, we found considerable heterogeneity in splicing efficiency among these introns, with a 
large number of splicing “outliers” which remain significantly unspliced throughout a 
stimulation time-course.  One explanation for such outliers comes from analysis of splice 
donor sequences.  A number of poorly spliced introns contained evolutionarily conserved 
weak 5’ splice donors.  However, there were a significant number of introns that did not 
contain such sequences, which suggests splice donor strength is just one of the regulatory 
mechanisms responsible for poor splicing.  It is likely factors like intron GC content, size, 
branch point strength, and 3’ splice site strength, which have been shown to correlate with 
poor splicing in other work29, contribute to the observed poor splicing efficiency of given 
junctions.  To determine more specifically the rates of slowly splicing introns, we used ActD 
to stall transcription and monitor intron half-lives.  Supporting the idea of heterogenous rates 
of splicing, while most introns spliced within 20-40s, some were delayed significantly and 
took >5 minutes to splice.   
  
37 
The fact that these inefficiently spliced introns occur in important inflammatory 
genes, some with the seemingly negative characteristic of having an evolutionarily conserved 
poor splice donor sequence, begs the question as to why they exist?  We hypothesize that 
these junctions act to either slow-down, or limit gene expression.  Again, at the heart of an 
inflammatory response is a tightly regulated gene expression program. Regulation of this 
gene expression program is crucial, as small changes can shift the balance away from 
protective immunity toward either nonexistent or destructive immunity.  Regulation at the 
post-transcriptional level through splicing can allow a cell the ability to quickly fine-tune 
when and how much of a given gene product is produced without altering the transcriptional 
landscape of a cell. With respect to the transcripts containing poorly spliced introns, it stands 
to reason the weak introns acts to dampen protein output, perhaps as a means to mitigate 
what otherwise would be an unchecked or inappropriately scaled response.  As splicing 
inherently involves a variety of trans-acting factors, future work aimed at identifying such 
factors that potentially regulate such splicing events will be important to our understanding 
of this form of post-transcriptional regulation.   
In conclusion, the hybrid capture approach provides a large number of junctional 
sequencing reads, which permitted unique insight into the efficiency and kinetics of splicing 
of mature transcripts, and revealed surprising heterogeneity. We suggest that this 






Materials and Methods 
 
Animals  
The California Institute of Technology Institutional Animal Care and Use Committee 
approved all experiments. C57BL/6 WT mice were bred and housed in the Caltech Office of 
Laboratory Animal Resources (OLAR) facility. C56BL6/J mice were sacrificed via CO2 
euthanasia and sterilized with 70% ethanol. Femur and tibia bones harvested and stripped of 
muscle tissue. Bone marrow cells were resuspended in 20mL of fresh DMEM. 2.5 *106 
bone-marrow cells plated in a 150mm dish in 20mL of BMDM Media (DMEM, 20% FBS, 
30% L929 condition media, and 1% Pen/Strep) and grown at 5% CO2 and 37°C. BMDM 
media was completely replaced on day 3 as well as a supplemental addition of 5mL L929 
condition media on day 5.  
 
Cell Culture  
Human embryonic kindey cells (HEK293T) from ATCC were cultured in DMEM 
supplemented with 10% FBS and 1% Pen/Strep. Cell lines were maintained at 37°C in 5% 
CO2. 
 
RNA Fractionation  
Confluent 10-cm dish of mature BMDMs were scraped into 400mL cold NP-40 lysis buffer, 
APJ1 (10mM Tris-HCl (pH 7.5), 0.08% NP-40, 150mM NaCl). Lysed cells layered onto 
1mL cold sucrose 322 cushion, APJ2 (10mM Tris-HCl (pH 7.5), 150mM NaCl, 24% w/v 
sucrose) and centrifuged for 10min at 4°C and 13000 rpm. The supernatant from this spin 
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represents the cytoplasmic RNA fraction, which is immediately added to 3 volumes of 100% 
ethanol and 2 volumes of buffer RLT (4M GuSCN, 325 0.1M b-mercaptoethanol, 0.5% N-
lauroyl sarcosine, 25mM Na-citrate, pH7.2) and stored at 80°C until ready to purify RNA. 
Pellet, containing intact nuclei, is resuspended in 500mL TRIzol reagent. If the pellet was 
difficult to dissolve, it was heated at 50°C with occasional vortexing. 100mL chloroform 
added and shaken vigorously for 15-20 s; allowed to phase separate at room temperature for 
5min. Tube centrifuged at 4°C and 12000 x g for 15min. Clear upper aqueous phase removed 
to a new tube, ensuring white DNA mid-phase is not removed, and is immediately added to 
3 volumes of 100% ethanol and 2 volumes of buffer RLT and stored at 80°C until ready to 
purify RNA. RNA is purified according to QIAGEN RNeasy column protocol and eluted in 




cDNA is added to biotinylated RNA probes, generated by Ampliscribe T7-Flash Biotin Kit 
(Epicentre), and incubated at 74°C for 4.5min to denature followed by addition of 1 volume 
of 2X hybridization (HYB) buffer (1M LiCl, 40mM Tris-HCl (pH 7.5), 20mM EDTA (pH 
8.0), 4M Urea, 0.5% Triton X-100, 1% SDS, 0.2% Na-deoxycholate). Reaction incubated at 
70°C for 30min. 0.3mg BioMag streptavidin beads (Bang Laboratories Inc.), washed 3 times 
in 1X HYB buffer, added and reaction incubated at 70°C and 1100rpm for 20min to capture 
cDNA-probe complex. Beads pelleted on magnet, followed by 2 washes of 150µL with 
preheated 1X HYB at 70°C, 1 wash of 150µL with wash #4 (160mM LiCl, 20mM Tris-HCl 
(pH 7.5), 10mM EDTA (pH 8.0), 2M Urea, 0.25% Triton X-100, 0.5% SDS, 0.1% Na-
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deoxycholate), and 1 final wash with wash #5 (40mM LiCl, 20mM Tris-HCl (pH 7.5), 10mM 
EDTA (pH 8.0), 2M Urea, 0.25% Triton X-100, 0.5% SDS, 0.1% Na-deoxycholate). Beads 
resuspended in 35µL of base elution buffer (125mM NaOH, 10mM EDTA (pH 8.0), 10mM 
Tris-HCl (pH 7.5) and incubated at 74°C and 1100rpm for 5min. Beads pelleted and 30µL 
cDNA containing supernatant removed to a new tube. Solution neutralized with 6.25µL 
neutralization buffer (800mM HCl, 160mM Tris-HCl (pH 7.5), 20mM EDTA (pH 8.0)). 
Immediately after neutralization, cDNA purified by 1.0X Sera-Mag treatment as described 
previously above and eluted in 45µL and stored at -80°C.  
 
RNA-Sequencing Analysis  
Sequencing was performed on a HiSeq 2500 High Throughput Sequencer (Illumina). Single-
end 50-mer reads were aligned using Tophat v2.1.130. Gene expression was determined using 
























Figure 1. (A) Schematic of RAP.  Biotinylated nucleotide probes are first hybridized to 
cDNA.  This probe-cDNA complex is then bound to streptavidin magnetic beads, which 
allows for non-hybridized sequences to be washed away.  The “captured” cDNA is then 
eluted from the beads and ultimately sequenced.  (B) A comparison of the total transcripts 
pulled down by the A20, IκBɛ, TNFα, and IκBα probes as compared to the non-targeted 
RPL32.  (C) Fold depletion of transcripts following “hybrid-capture” in log scale.  (D) As in 
(C) but in linear scale.  
 
Figure 2. (A) Comparison of reads that map to NF-κB transcriptome with hybrid capture or 
without hybrid capture. (B) Number of reads that map to the NF-κB transcriptome (left) and 
number of reads sequenced (right).  (C) Percent of reads that map to the NF-κB transcriptome 
with hybrid capture (red) or without hybrid capture (blue). 
 
Figure 3. (A) CoSI metric is a ratio comparing the number of reads that map across a splice 
junction to the number of reads that contain partial intron and exon sequences.  A CoSI value 
of 1 indicates that a junction is completely spliced, whereas a CoSI value of 0 indicates that 
no splicing has occurred.  (B) A plot depicting the change in CoSI for chromatin-associated 
RNA at different timepoints of TNFα stimulation.  (C) The RefSeq annotation and the 
sequencing reads for the 20 minute timepoint are shown below the CoSI plot. (D) Plot 




Figure 4. (A) Tukey boxplot representing CoSI values at different TNFα stimulation time 
points.  The top of the ‘box’ represents the 75th percentile value; the bottom of the ‘box’ 
represents the 25th percentile value.  The space between represents the interquartile difference 
(IQR) and the line inside the box represents the mean CoSI value.  The ‘whisker’ is calculated 
by subtracting 1.5*IQR from the 25th percentile.  Values lower than the whisker are classified 
as ‘outliers’.  (B) Histogram of RNA-seq reads for IRF7 throughout a TNFα stimulation 
time-course.  The retained fourth intron is highlighted in yellow. 
 
Figure 5. Histogram of RNA-seq reads for CD40 (A) and DAXX (B) throughout a TNFα 
stimulation time-course.  The retained intron is highlighted in yellow. 
 
Figure 6. (A) A depiction of the sequencing reads that map to the IL27 gene at 40 minutes 
of TNFα stimulation.  (B) Consensus sequence for splice donors.  The first four bases are 
usually gtaag or gtgag.  (C) The mouse NCBI37/mm9 RefSeq annotation for IL27. The 
fourth intron has the sequence gtaga, which differs from the consensus sequence.  (D) A 
comparison of the splice donor sequence for the fourth intron of IL27 shows the sequence is 
conserved across a variety of species.  
 
Figure 7. (A) Histogram of RNA-seq reads showing induction of IκBα in response to TNFα 
and ActD.  Time at which TNFα and ActD are added is depicted.  (B) Histogram of intron 
half-lives.  (C) Scatter plot representing the intron half-life on the x-axis and the minimum 




Figure 8. (A) Tukey boxplot representing CoSI values at different TNFα stimulation time 
points for early, intermediate, and late induced genes. (B) Expression data from the Smale 
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Intron retention (IR) has emerged as an important mechanism of gene expression control, but 
the factors controlling IR events remain poorly understood. We observed consistent IR in 
one intron of the Irf7 gene and identified BUD13 as an RNA-binding protein that acts at this 
intron to increase the amount of successful splicing. Deficiency in BUD13 was associated 
with increased IR, decreased mature Irf7 transcript and protein levels, and consequently a 
dampened type I interferon response which compromised the ability of BUD13-deficient 
macrophages to withstand VSV infection. Global analysis of BUD13 knockdown and 
BUD13 cross-linking to RNA revealed a subset of introns that share many characteristics 
with the one found in Irf7 and are spliced in a BUD13-dependent manner. Deficiency of 
BUD13 led to decreased mature transcript from genes containing such introns. Thus, by 















Three forms of alternative processing of a pre-mRNA have been described: differential 
inclusion of an exon, alternative splice site selection, and intron retention (IR).  The latter, 
IR, has emerged as a previously underappreciated mechanism of post-transcriptional gene 
regulation.  Unlike the two alternative splicing events, IR rarely contributes to proteomic 
diversity (Schmitz et al., 2017).  However, IR events have the ability to act as negative 
regulators of gene expression by: (1) delaying onset of gene expression by slowing down 
splicing kinetics (Hao and Baltimore, 2013), (2) increasing potential nuclear degradation by 
nuclear exosomes, (3) increasing potential cytoplasmic degradation by nonsense mediated 
decay (Wong et al., 2016). 
Recent genomic studies suggest IR plays an important role in the regulation of gene 
expression in a wide range of processes including cellular differentiation (Wong et al., 2013; 
Yap et al., 2012) and tumorigenesis (Dvinge and Bradley, 2015).  Further, widespread IR 
throughout mouse and human cell and tissue types has led to the idea that IR events act to 
functionally “tune” the transcriptome of a cell (Braunschweig et al., 2014).  However, with 
few exceptions, the factors that control IR events and thus potentially shape gene expression 
programs of cells, remain poorly understood.  
Irf7 is an interferon-inducible master regulator of the type-I interferon-dependent 
immune response and is crucial to the production of interferon-α and β (Honda et al., 2005).  
Aberrant IRF7 production is linked to a wide range of pathologies, from life-threatening 
influenza (Ciancanelli et al., 2015) to autoimmunity (Harley et al., 2008), because precise 
regulation of Irf7 ensures a proper immune response. Notably, intron 4 of Irf7 is short, GC-
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rich, and has a poor splice donor sequence, characteristics shared by many poorly spliced 
introns.  We and others have previously shown that intron 4 of Irf7 splices inefficiently 
(Shalek et al., 2013), affecting gene expression and opening a new line of inquiry as to the 
mechanism of IR regulation in Irf7.  
Using RNA antisense purification-mass spectrometry (RAP-MS) (McHugh et al., 
2015), we identified the protein BUD13 as one that regulates IR in Irf7.  BUD13 was found 
to aid splicing efficiency and expression of the Irf7 mature transcript and protein, thus 
promoting the downstream type-I interferon-dependent immune response.  We show that 
IRF7 is able to trigger a robust interferon response in the presence but not in the absence of 
BUD13.  Further, BUD13 was found to increase the splicing efficiency of a multitude of 
other junctions with similar characteristics to the one found in Irf7.  By aiding in splicing 
efficiency, BUD13 limits intron retention and increases gene expression levels of transcripts 
containing BUD13 dependent junctions.  
 
RESULTS 
Irf7 contains an intron that splices poorly following stimulation.  
To study the role of mRNA splicing during an innate immune response, we sequenced the 
RNA from mouse bone marrow-derived macrophages (BMDMs) stimulated with TNFα.  
From this sequencing, we identified an increased number of reads in the fourth intron of the 
most abundant transcript of Irf7 as compared to other introns in the transcript (Figure 1A). A 
variety of features of this intron make it a likely candidate for retention (Braunschweig et al., 
2014).  It is extremely small at 69 nucleotides and has a high G/C content in both the flanking 
exons and within the intron itself (Figures 1B-E).  Furthermore, the intron contains a ‘weak’ 
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5’ splice site, one that deviates from a consensus splice site sequence.  This is quantified 
using a maximum entropy model to calculate the splice site quality score (Figure 1F) (Yeo 
and Burge, 2004).  This increase in the number of intron reads at the fourth intron as 
compared to neighboring introns is also seen upon induction of Irf7 with Poly(I:C) and IFNα 
(Figures 1G, H). 
To quantify the extent of retention across RNA-seq data-sets, we use a metric we 
designate the “splicing ratio” (SR) (Figure 1I; see methods), which is a length normalized 
ratio of intronic reads to total reads at each junction.  Low SR values indicate a junction is 
primarily spliced, whereas high SR values indicate a junction is primarily unspliced.  Of note, 
junction reads that map across intron-exon boundaries are called unspliced as they can only 
be derived from a transcript that has yet to splice at the given junction.  This can lead to some 
discrepancy when comparing SR with the histogram of RNA-seq reads as reads that map 
only a few base pairs into the intron do not easily appear unspliced but come from unspliced 
transcripts and count exclusively as unspliced in the SR value calculation (see methods).  
Using this metric, we quantified the extent of retention for all junctions in the most abundant 
Irf7 transcript.  We observed that for all types of stimulation, the retention of the fourth intron 
of the transcript is much greater than that seen for any of the other introns (Figures 1J and 
S1A, B). This intron remains poorly spliced despite the fact that there is clear excision of 
neighboring introns.  It is worth noting that quantitation of the IFNα stimulation shows 
increased intronic signal throughout the Irf7 transcript.  This increased intronic signal is due 
to faster and stronger induction of Irf7 via stimulation with IFNα and as such, an increase in 
the amount of pre-mRNA at a given stimulation time-point.  Despite this increase in intronic 
signal throughout the transcript, we observed a corresponding increase in the level of 
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retention for the poorly spliced fourth intron (Figures 1J, S1B).  Thus, we conclude this intron 
of Irf7 splices poorly following many forms of stimulation. 
 
RAP-MS identifies BUD13 as an RNA binding protein that interacts with Irf7 mRNA. 
To understand how cells handle a retained intron, we sought to identify trans-acting proteins 
that might affect the process using RNA Antisense Purification followed by Mass 
Spectrometry (RAP-MS) (Figure 2A) (McHugh et al., 2015).  RAP-MS employs antisense 
biotin-containing ssDNAs complementary to Irf7 exons to purify the proteins associated with 
the total pool of Irf7 transcripts, containing both nascent pre-mRNAs and mature mRNA. 
Using this proteomic approach, we identified the RNA-binding protein BUD13 to be highly 
enriched (~6-fold) on Irf7 transcripts as compared to β-actin transcripts, which were used as 
a control (Figure 2B, Table S2).  Bud13 has been characterized in yeast as a member of the 
Retention and Splicing complex (RES) (Dziembowski et al., 2004), forming a trimeric 
complex with Pml1p and Snu17p, and aids in the splicing and nuclear retention of a subset 
of transcripts. It is not well characterized in mammalian systems.  We captured a variety of 
other known RNA-binding proteins (PUM2, PRPF40a, SON); however, no other protein was 
enriched greater than two fold on Irf7 transcripts.  We observed specificity in the RNA 
antisense purification for the intended transcripts (Figure 2C).    
Following RAP-MS, we confirmed BUD13 enrichment on Irf7 transcripts by 
performing RNA Immunoprecipitation (RIP) followed by qPCR.  Using formaldehyde cross-
linked, BMDMs stimulated with TNFα for 30 minutes or Poly(I:C) for 12 hours, we observed 
>7-fold enrichment of Irf7 transcripts associated with Bud13 immunoprecipitates as 
compared to Rabbit IgG control immunoprecipitates (Figures 2D, E).  Of note, despite using 
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two different stimuli, we found similar levels of enrichment. In contrast, no differential 
enrichment of Rpl32 was observed.  Thus, isolating the proteins associated with Irf7 mRNA 
transcripts led to the identification of BUD13, and immunoprecipitation of BUD13 protein 
confirmed enrichment of Irf7 mRNA.   
 
Bud13 knockdown leads to increased retention in the weak Irf7 intron. 
To determine whether the enrichment of Bud13 had an effect on Irf7 mRNA processing, we 
used an shRNA approach to knockdown Bud13 protein levels in BMDMs (Figures S2A, B).  
To quantify differences in splicing between the shBud13 sample and the scrambled control 
sample, we calculated the difference in the previously mentioned splicing ratio (SR) metric 
between shBud13 and control for each junction at each time point.  This resulting value was 
designated ΔSR. A positive ΔSR indicates a junction is more unspliced in the shBud13 
sample while a negative ΔSR indicates a junction is more unspliced in the control sample.  
RNA-seq was performed on RNA from unstimulated BMDMs, as well as macrophages 
stimulated with TNFα for 0, 30, 60, and 120 minutes.  Bud13 knockdown led to a further 
increased retention of the fourth intron in Irf7 (Figure 3A – highlighted intron, S2C).  Further, 
the sequencing coverage plots showed little variation in splicing for the other seven introns 
in the transcript.  This was confirmed when splicing was quantified using the ΔSR metric 
(Figure 3B).  At all stimulation time-points, the ΔSR value for the fourth intron was 
significantly greater than zero, indicating an increase in retention when BUD13 levels were 
reduced.  There is a significant difference in the ΔSR of intron 4 as compared to every other 
junction in the Irf7 transcript (p<0.001, Student’s t-test).  All other pairwise comparisons are 
insignificant.  This splicing difference at the fourth intron was confirmed via RT-PCR 
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(Figure 3C).  It appears that BUD13 plays a specific role of aiding in the excision of the 
poorly spliced junction but is not required for total splicing of other introns in the transcript, 
at least as indicated by the partial knockdown with an shRNA.  We next looked at how this 
retention affected the induction kinetics of Irf7.  We observed decreased induction of Irf7 
mRNA in response to TNFα stimulation in shBUD13 BMDMs as compared to control 
BMDMs (Figure 3D), consistent with the idea that intron retention leads to transcript 
degradation (Jacob and Smith, 2017).  Other TNFα induced transcripts that lacked a BUD13 
dependent splicing defect showed similar induction between the time-courses (Figures S2 D-
F). 
 
BUD13 knockdown alters the type I interferon response. 
Because Irf7 is known as a ‘master regulator’ for robust type I interferon production (Honda 
et al., 2005), we next investigated the effect of BUD13 knockdown on a type I interferon 
response. To do so, we stimulated BMDMs with the TLR3 agonist Poly(I:C) for up to 24 
hours.  Activation of TLR3 leads to the production of type I interferons followed by the 
downstream induction and activation of Irf7, which serves to amplify the type I interferon 
response via positive feedback (Ciancanelli et al., 2015). We again observed differential 
splicing between the shBUD13 samples and the control samples in intron 4 of Irf7 (Figures 
4A, S3A).  As before, there is a significant difference in the ΔSR of intron 4 as compared to 
every other junction in the Irf7 transcript (Figure 4B. p<0.001, Student’s t-test), whereas all 
other pairwise comparisons are insignificant.  As is the case with TNFα, knocking down 
BUD13 altered Irf7 induction kinetics.  Less Irf7 mRNA is induced at 240, 720, and 1440 
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mins of poly(I:C) stimulation (Figure 4C).  This reduction in Irf7 mRNA leads to a decrease 
in the amount of IRF7 protein produced (Figure 4D).   
Next we looked at how this reduction in IRF7 would alter the production of RNA 
from interferon signature genes (ISGs).  Expression of 119 ISGs (selected based on 
upregulation in response to IFNα; see methods) (Mostafavi et al., 2016) was examined. In 
unstimulated BMDMs, used as a baseline, the median log2 expression fold change (FPKM 
shBUD13/ FPKM control) is 0.1655 (Figure 4D).  In contrast, at 720 mins of stimulation, 
the median log2 expression fold change shifts to -0.1007 (Figure 4E), indicating a significant 
decrease in ISG expression in the shBUD13 sample compared to the control sample at this 
time-point compared to the baseline (Wilcoxon rank-sum, P<0.001). This significant 
decrease in ISG expression remained true when comparing any of the ‘early’ timepoints (0, 
15, 60 mins) to any of the ‘late’ timepoints (240, 720, 1440 mins) (Figure 4G, Wilcoxon 
rank-sum, P<0.001). qPCR was used to monitor expression of both IFNα and IFNβ 
following 720 and 1440 mins of Poly(I:C) stimulation.  We observed significant reduction 
in both when comparing the shBUD13 samples to the control samples (Figures 4H, I).  To 
ensure differential expression of ISGs was not due to splicing defects from BUD13 
knockdown, we quantified the ΔSR for every ISG junction at 720 mins.  The fourth intron 
of Irf7 has the greatest ΔSR at 0.227. Only four other junctions of the 375 that were examined 
have ΔSRs greater than 0.1, and the majority of junctions have ΔSRs close to 0 (Figure S3C 
and Table S3; mean = 0.002, median = 0).  Similar results were obtained when BMDMs 
were stimulated with the TLR9 agonist CpG (Figures S4A-E). Taken together, we conclude 
that Bud13 deficiency results in a highly compromised type I interferon response. 
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We next examined whether Irf7 pre-mRNA with a retained fourth intron was able to 
exit the nucleus and enter the cytoplasm.  BMDMs were stimulated with poly(I:C) and 
fractionated into a nuclear fraction (containing the nucleoplasm and chromatin) and a 
cytoplasmic fraction. RNA-seq was performed on both fractions.  In the cytoplasm, we found 
Irf7 mRNA to be completely spliced (Figures 4J, K).  Thus, unspliced Irf7 is either being 
degraded in the nucleus, or it makes it to the cytoplasm and is degraded extremely quickly, 
such that virtually no signal can be detected via RNA-seq.  Furthermore, in support of our 
whole cell sequencing data and IRF7 immunoblots, we observed less Irf7 mRNA in the 
cytoplasm in shBUD13 samples as compared to control samples (Figure 4L).  Finally, 
although we notice a large number of unspliced reads in the nucleus at all junctions in both 
samples, the fourth intron had a greater nuclear RPKM in shBUD13 compared to control 
BMDMs across the stimulation time-course (Figure 4K) and had a significantly greater 
nuclear ΔSR as compared to any other junction in the transcript (Figure S4G). 
 
Global analysis of the role of BUD13 in BMDMs. 
We next investigated global splicing differences caused by Bud13 knockdown.  Using the 
TNFα stimulated data-set, ΔSR was calculated for every junction in every expressed gene.  
We found that a number of other transcripts had a Bud13 dependent junction (Figure 5A).  
Of note, the fourth intron of Irf7 is among the most BUD13 dependent junctions in both the 
TNFα and Poly(I:C) data-sets (Figures 5A and S5H, see methods for analysis details).  
Similar to the case with Irf7, almost all transcripts contain only a single Bud13 dependent 
junction, even when low thresholds are used to quantify dependency (Figure 5B).  To 
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determine whether splicing differences caused by BUD13 knockdown led to altered gene 
expression, we compared the effect of the BUD13 knockdown on genes that contained a 
BUD13 dependent junction to those that did not. (see methods).  The median log2 expression 
fold change (FPKM shBUD13/ FPKM control) for genes containing a BUD13 dependent 
junction was -0.5084.  In contrast, the median log2 expression fold change (FPKM shBUD13/ 
FPKM control) for genes without any junctions affected by Bud13 knockdown was -0.2170.  
Thus, we conclude there is an inverse relationship between IR due to BUD13 knockdown 
and gene expression (Wilcoxon rank-sum, P< .01) (Figure 5C).   
Next, it was of interest to us to identify sequence elements that led BUD13 to have its specific 
splicing effect. The most evident element to explore was the effect of splice site strength on 
BUD13 dependent splicing.  Previous work has shown that the yeast orthologue of Bud13 
plays a role in efficient splicing for a junction with a weak 5’ splice site (Dziembowski et al., 
2004).  Further, the junction affected in Irf7 has a non-consensus 5’ splice site.  To investigate 
this issue, we first quantified every 5’ and 3’ splice site using a maximum entropy model 
(Yeo and Burge, 2004). Then, we took progressively weaker splice site thresholds, and 
compared the mean ΔSR for every junction below that threshold to the mean ΔSR of every 
junction in the data-set (Figure 5D).  We saw that as the splice site threshold for the 5’ splice 
site became progressively weaker, the mean ΔSR for junctions weaker than that threshold 
increased and thus there was a greater BUD13 splicing effect.  This result was not seen when 
the same analysis was applied to the 3’ splice site.  In support of a 5’ splice site dependency 
for a BUD13 effect, we noticed differences in the 5’ splice site motif of BUD13 dependent 
junctions as compared to to all expressed junctions (Figure 5E).  
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We then analyzed the BUD13 splicing effect with respect to other features known to 
correlate with IR (Braunschweig et al., 2014).  Across all time-points for both TNFα (Figures 
5F-H) and Poly(I:C) (Figures S5 A-C), BUD13 dependent introns were dramatically smaller 
and had increased G/C content in both the intron and in the flanking exons.  We also noticed 
that the distance from the branch point to the 3’ splice site was smaller in the BUD13 
dependent introns than in the total data-set (Figures 5I and S5D).  This could be a byproduct 
of the smaller intron length; however, it is of interest because BUD13 has been shown in 
yeast to bind just downstream of the branch point (Schneider et al., 2015).  A significant 
difference was not seen in branch point strength and BUD13 splicing effect (Figures S5 E, 
F).   
Finally, as IR is only one form of alternative splicing, we looked at whether other 
forms of alternative splicing were affected by Bud13 knockdown.  We found that the 
majority of statistically significant alternative splicing events involved intron retention 
(Figure S5G, see methods).  Of the 42 alternative splicing events that were significant in 
multiple data-sets upon BUD13 depletion, 27 involved intron retention, 9 involved a skipped 
exon, and the remaining 6 involved either an alternative 3’ or 5’ splice site.  IR at intron 4 in 
Irf7 was the only alternative splicing event that occurred in transcripts related to the type I 
interferon response. 
 
eCLIP shows enrichment on Bud13 dependent junctions near the 3’ splice site. 
Next we used enhanced crosslinking and immunopreciptation (eCLIP)-seq data from the 
ENCODE Project Consortium(Consortium, 2012) to investigate BUD13 binding specificity 
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across the genome.  We found that in K562 and Hep G2 cells, the majority of Bud13 eCLIP-
sequencing reads were located downstream of the branchpoint near the 3’ splice site (Figures 
6A, B), consistent with what is seen in yeast (Schneider et al., 2015).  Plots are shown as a 
measure of binding over input.  There is some read density near the 5’ splice site, which we 
hypothesize is due to BUD13’s association with the spliceosome.  Although BUD13 may 
not bind near the 5’ splice site, factors in the spliceosome that interact with BUD13 may 
immunoprecipitate with it, leading to 5’ signal.  Data for SF3B4 and PRPF8, known RBPs 
that interact with the 3’ and 5’ splice site respectively, is also shown for comparison (Figures 
6A, B).  Additionally, it was expected that BUD13 binding would correlate with BUD13 
activity.  To test this hypothesis, we used knockdown data from the ENCODE Project 
Consortium to determine BUD13 dependent junctions in K562 and Hep G2 cells.  In K562 
cells, we noticed that there was a significant increase in BUD13 binding over input at BUD13 
dependent junctions (Figure 6A).  In Hep G2 cells, this increase was less pronounced (Figure 
6B); however, we note that we found BUD13 knockdown had a much greater impact in K562 
cells as compared to Hep G2 cells (Figure S5I).  In order to survey a large enough selection 
of junctions in Hep G2’s, we had to significantly lower our threshold for what was deemed 
a BUD13 dependent junction (see methods), which in turn might explain the dampened 
BUD13 binding/activity relationship in Hep G2.  We conclude that Bud13 either 
preferentially associates with these BUD13 dependent junctions or associates with them for 
a longer period of time.   
We then performed peak calling to determine the location of significant peaks.  We 
found the majority of peaks are in intronic regions or intron-exon junctions and that most of 
the peaks that lie in intron-exon junction are located at the 3’ junction (Figures 6C, D).  As 
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might be expected from knockdown data, when comparing introns that have an overlapping 
eCLIP peak to all introns from expressed transcripts, we see both a length and G/C% bias 
(Figures 6E, F).  BUD13 peaks tend to fall in smaller introns that are GC rich, a finding 
consistent with the ΔSR data.  Lastly, a list of the GO biological processes most enriched 
from the list of peaks in K562 and Hep G2 cells is shown (Figure 6G).   
 
Bud13 knockdown alters the BMDM response to VSV. 
Vesicular stomatitis virus (VSV) is a (-)ssRNA virus known to induce type I IFN through 
TLR7 (Lund et al., 2004).  To test whether impairment of IRF7 due to BUD13 knockdown 
was present in VSV stimulated BMDMs, we infected both shBUD13 and control BMDMs 
at an MOI of 5 and 10.  At all time-points throughout infection in both MOIs, there was 
dampened IRF7 induction (Figures 7A, B) as quantified by Taqman qPCR.  Next, in order 
to determine the consequences of impaired IRF7 induction, we determined the yield of virus 
from BMDMs following a period of infection with a given input MOI. shBUD13 BMDMs 
produce significantly more VSV as compared to control BMDMs (Figure 7C).  This 
difference in viral production is presumably due to decreased production of IRF7 associated 
with depletion of BUD13 and the corresponding dampened type I interferon response.  To 
test the extent to which this increase in viral production following BUD13 depletion was due 
to impairment of IRF7, we rescued IRF7 levels by expressing Irf7 cDNA either in the context 
of the BUD13 knockdown or the control.  We found overexpression of Irf7 cDNA effectively 
rescues the ability for a cell to clear virus (Figure 7C).  As such, we conclude that the viral 
susceptibility associated with BUD13 knockdown is due primarily to the inefficient 




In this study, we sought proteins that might relate to the poor splicing of an intron in Irf7 
transcripts.   Using RAP-MS, we identified BUD13 as a protein that has the ability to increase 
splicing of the Irf7 intron.  In the absence of BUD13, in response to inflammatory stimulus, 
macrophages produced Irf7 with increased intron retention (IR) and notably less mature Irf7 
transcript and protein (Figures 3C, 4C, 4D, S4C).  Irf7 is the interferon-inducible master 
regulator of the type-I interferon-dependent immune response (Honda et al., 2005).  
Correspondingly, depletion of BUD13 led to a general reduction in ISG and cytokine 
production, implying a compromised type I interferon response (Figures 4E-J, S4D-G).  This 
splicing and corresponding expression defect upon BUD13 depletion was observed under 
various stimulation regimens and times. We found that macrophages deficient for BUD13 
were strikingly more susceptible to infection by VSV, presumably owing to the reduction in 
Irf7 transcript levels (Figure 7). 
We observed the BUD13 splicing dependence in other introns of other genes.  A 
number of short, GC-rich introns with non-consensus splice donor sites were excised 
inefficiently when BUD13 levels were depleted (Figure 5).  As was the case with Irf7, this 
increased IR reduced mature transcript levels (Figure 5A).  Transcripts containing retained 
introns have been shown in the literature to be degraded by two mechanisms: (1) nuclear 
degradation via the RNA exosome, (2) cytoplasmic degradation upon detection of a pre-
termination codon (PTC) via the NMD decay machinery.  Although the majority of these 
introns contain a PTC, it remains to be determined whether degradation is occurring in the 
nucleus or cytoplasm (Jacob and Smith, 2017; Sayani and Chanfreau, 2012) 
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Bud13 was originally identified as a part of a “Retention and Splicing” (RES) 
complex (Dziembowski et al., 2004) in yeast. However, yeast Bud13 (ScBud13) and 
mammalian BUD13 are significantly different lengths (266 vs. 637 amino acids) (Na et al., 
2016), with only the mammalian protein containing a large, disordered arginine-rich N-
terminal domain.  ScBud13 counteracts IR in introns within the mediator complex, mating 
genes, and tRNA modifying genes (Ni and Snyder, 2001; Zhou et al., 2013; Zhou and 
Johansson, 2017), which in turn impair yeast budding.  In connection with the RES complex, 
ScBud13 is thought to safeguard formation of the ‘Bact complex’ of the spliceosome (Bao et 
al., 2018).  In the Bact stage, the 5’ splice donor and branch point are recognized by the 
spliceosome. However, progression to catalysis of the first step of the splicing reaction 
requires remodeling of several spliceosome components (Ohrt et al., 2012).  Lack of the RES 
complex has been shown to lead to premature binding of Prp2, a quality control factor that 
is responsible for spliceosome remodeling as well as the disassembly of suboptimal 
substrates.  It has been hypothesized that ScBud13 and the RES complex temporally regulate 
Prp2 binding (Bao et al., 2018).  In the mammalian context, short, GC-rich introns with weak 
donor sites may be particularly susceptible to Prp2-mediated disassembly, which may 
explain the specificity of IR events upon BUD13 depletion. 
In yeast, differential studies using mass spectrometry (Fabrizio et al., 2009) and 
cross-linking have established that some ScBud13 is detectable in preparations of stalled B, 
Bact, and B* complexes. One cryo-EM structure of the yeast spliceosome found density 
corresponding to ScBud13 in a stalled Bact pre-catalytic complex, although a structure of the 
stalled B complex found only weak density for ScBud13 (Plaschka et al., 2017; Zhou and 
Johansson, 2017).  In mammals, structural evidence of BUD13 is limited. Given the partial 
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sequence homology between all members of the yeast RES complex and their mammalian 
counterparts, it is not surprising that BUD13 (and other RES complex members) are often 
undetectable in preparations of stalled spliceosomes using cross-linking and mass-
spectrometry. Furthermore, BUD13 was not detected in a recent human cryo-EM structure 
of a stalled B complex (Bertram et al., 2017).  Taken together, it is not yet possible to 
determine if the sub-stoichiometric nature of BUD13 in mammalian spliceosome complexes 
is because it is constitutively associated but highly transient or because it serves as a non-
essential accessory to spliceosome function. Cryo-EM studies, as well as single molecule 
studies, would seem to suggest compositional heterogeneity of the spliceosome, and that the 
BUD13-endowed spliceosome may catalyze the splicing reaction in a fundamentally 
different way than is used in its absence (Bao et al., 2018; Blanco et al., 2015; Hoskins and 
Moore, 2012). 
Recently, the RES complex in zebrafish was shown to regulate levels of IR in short, 
GC-rich introns in knockout studies (Fernandez et al., 2018).  Indeed, both in Zebrafish 
(Fernandez et al., 2018) and C. Elegans (Jiang et al., 2001), deficiency of RES components 
has been reported to lead to embryonic lethality.  Our results show that mammalian BUD13 
shares this splicing fidelity function, and deficiency may prevent proper development.  
Despite this, knockdown and knockout cell lines have displayed no overt growth defects, 
suggesting a developmental but not immune-cell intrinsic dependence on BUD13 for 
survival.  Of note, we did knockdown the other components of the RES complex, RBMX2 
and SNIP1 (Figure S7).  We found that the fourth intron of Irf7 has a largest ΔSR as 
compared to other introns in the transcripts (Figure S7B) and that there is some global IR 
upon knockdown (Figure S7C); however, these effects are very slight as compared to what 
  
72 
is observed with BUD13 depletion.  It might be that more efficient knockdowns or a total 
knockout of these components is needed to replicate the strong effect seen with BUD13 
depletion, or alternatively that there is some redundancy with these components in 
mammalian cells. 
With respect to Irf7, the fact that a crucial immunological gene has such an intron, 
with its variety of seemingly negative characteristics that make it difficult for the spliceosome 
to excise, begs the question as to why it exists.  At the heart of an inflammatory response is 
a tightly regulated gene expression program.  Regulation of this gene expression program is 
crucial as small changes can shift the balance away from protective immunity towards either 
nonexistent or destructive immunity (Kontoyiannis et al., 1999).  Here we’ve shown that 
alterations to the splicing efficiency of the fourth intron have the ability to significantly alter 
the functional output of IRF7.  Thus, by existing in the Irf7 transcript and commonly being 
retained, it stands to reason the weak fourth intron acts to dampen IRF7 output, perhaps as a 
means to mitigate what otherwise would be an unchecked or inappropriately scaled response.  
Whether a cell actively controls this splicing event and thus, the intron serves as a regulatory 
control point, remains unknown.  Further, it remains unknown whether BUD13 plays a role 
in this regulation or whether it simply represents a mechanism that evolved to counter intron 
retention in a subset of introns that require splicing but happen to be inherently weak. 
In summary, we found that BUD13 modulates gene expression through its ability to 
alter IR, often in notably small, GC-rich introns with weak splice sites.  Deficiency of BUD13 
results in IR and concomitant decreased gene expression in transcripts such as Irf7, 
dampening the type I interferon response and increasing viral susceptibility.   Therefore, in 
mediating Irf7 gene expression, BUD13 presents a potential therapeutic target for the 
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treatment of infections or autoimmune conditions.  Future studies should seek to understand 
why BUD13 is vital for the efficient splicing of only a subset of junctions and whether or not 
this junction specificity plays an active role in regulating gene expression. If modulated, this 
strategy by which components associated with the spliceosome rescue transcripts from intron 
retention and degradation may represent a previously underappreciated layer of regulation in 
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Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, David Baltimore (baltimo@caltech.edu). 
 
Experimental Model and Subject Detail 
Animals 
The California Institute of Technology Institutional Animal Care and Use Committee 
approved all experiments. C57BL/6 WT mice were bred and housed in the Caltech Office of 
Laboratory Animal Resources (OLAR) facility.  C56BL6/J mice were sacrificed via CO2 
euthanasia and sterilized with 70% ethanol. Femur and tibia bones harvested and stripped of 
muscle tissue. Bone marrow cells were resuspended in 20mL of fresh DMEM. 2.5 *106 bone-
marrow cells plated in a 150mm dish in 20mL of BMDM Media (DMEM, 20% FBS, 30% 
L929 condition media, and 1% Pen/Strep) and grown at 5% CO2 and 37°C. BMDM media 
was completely replaced on day 3 as well as a supplemental addition of 5mL L929 condition 
media on day 5.   
Cell Culture 
Human embryonic kindey cells (HEK293T) from ATCC were cultured in DMEM 








Knockdown Experiments  
BMDMs for knockdown experiments were grown as described above with a few additions. 
On days 3 and 4, retrovirus encoding shRNAs were added to cells.  On day 5, cells were 
selected with puromycin (5ug/mL).  On day 8, following ~72 hours of puromycin treatment, 
media was removed and 10mL of PBS w/ 2mM EDTA was added.  Depending on the 
experiment, cells were stimulated directly or lightly scraped and replated in 6-well plates or 
10-cm dishes for stimulation the following day. Stimulation involved with either 20ng/mL 




Total RNA was purified from BMDMs using TRIzol reagent (Ambion) as per the 
manufacturer’s instructions.  Genomic DNA in RNA purifications was eliminated through 
treatment with Turbo DNase (Thermo Fisher Scientific) for 30 min at 37°C.  0.1-1µg RNA 
and 1µM dT(30) oligo (d14-954: 5’-AAGCAGTGGTATCAACGCAGAGTACT(30)) was 
heated at 80°C for 2.5min followed by snap cooling on ice. 10µL template-switch RT mix 
added (10µM template-switch oligo (TSO: 5’-
AAGCAGTGGTATCAACGCAGAGTACACArGrGrG), 20mM DTT, 2X ProtoScriipt II 
Reverse Transcriptase Reaction Buffer (NEB), 1mM dNTPs, 40U Murine RNAse Inhibitor 
(NEB), and 200U ProtoScript II (NEB) Reverse Transcriptase. Reaction incubated in 
thermocycler with the following program: 1. 42°C for 30min, 2. 45°C for 30min, 3. 50°C for 




Confluent 10-cm dish of mature BMDMs were scraped into 400µL cold NP-40 lysis buffer, 
APJ1 (10mM Tris-HCl (pH 7.5), 0.08% NP-40, 150mM NaCl). Lysed cells layered onto 
1mL cold sucrose 322 cushion, APJ2 (10mM Tris-HCl (pH 7.5), 150mM NaCl, 24% w/v 
sucrose) and centrifuged for 10min at 4°C and 13000 rpm. The supernatant from this spin 
represents the cytoplasmic RNA fraction, which is immediately added to 3 volumes of 100% 
ethanol and 2 volumes of buffer RLT (4M GuSCN, 325 0.1M β-mercaptoethanol, 0.5% N-
lauroyl sarcosine, 25mM Na-citrate, pH7.2) and stored at -80°C until ready to purify RNA. 
Pellet, containing intact nuclei, is resuspended in 500µL TRIzol reagent.  If the pellet was 
difficult to dissolve, it was heated at 50°C with occasional vortexing.  100µL chloroform 
added and shaken vigorously for 15-20s; allowed to phase separate at room temperature for 
5min. Tube centrifuged at 4°C and 12000 x g for 15min. Clear upper aqueous phase removed 
to a new tube, ensuring white DNA mid-phase is not removed, and is immediately added to 
3 volumes of 100% ethanol and 2 volumes of buffer RLT and stored at -80°C until ready to 
purify RNA. RNA is purified according to Qiagen RNeasy column protocol and eluted in 
30µL nuclease-free H2O. RNA samples are DNAse treated with Turbo-DNAse and stored 
at -80°C. 
 
Library preparation and RNA-Seq Analysis 
Limited PCR amplifications was performed prior to library preparation.  PCR reaction done 
with KAPA HiFi HotStart 2x ReadyMix, 5% cDNA, and 1µM primer (d14-955: 5’-
AAGCAGTGGTATCAACGCAGAGTACT).  Thermal cycler programmed for 120 
seconds at 95°C as initial denaturation, followed by 14 cycles of 30sec at 95°C for 
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denaturation, 30sec at 62.5°C as annealing, 150sec at 72°C for extension, and final extension 
at 72°C for 5 min.  PCR reactions 0.9X SeraMag and eluted in 25µL. Concentrations of 
purified library determined using Qubit High Sensitivity dsDNA kit (Invitrogen) as 
described.  Full length cDNA libraries were barcoded using the Nextera XT Tagmentation 
protocol (Illumina).  
 
RNA-Antisense Purification 
RNA antisense purification-mass spectrometry (RAP-MS) was performed as described in 
McHugh et al. with a few alterations.  Briefly, we designed three 90-mer DNA 
oligonucleotide probes that were antisense to the complementary target RNA sequence in 
both Irf7 and Actb transcripts.  Each probe was targeted to a different location on the 
transcript and modified with a biotin in order to enable capture of DNA:RNA hybrids on 
streptavidin coated magnetic beads.   
RNA Prep and Lysis: ~250million cells, or 25 150mm plates of BMDMs were used for each 
capture. Following stimulation with TNFα (20ng/ml) for 30 minutes, ~5-10 mL of PBS w/ 
2mM EDTA was added to each plate and cells were removed by lightly scraping.  Cells were 
pelleted, resuspended in PBS, and poured into a new 150mm plate.  The cells were then 
crosslinked in Spectrolinker at 254 nm wavelength with 0.8 J/cm2 (instrument setting: 8000 
x 100 uJ/cm2).  Following crosslinking, cells were again pelleted, at which point the pellet 
could be frozen and stored at -80°C.  Cells were lysed in 2mL of lysis buffer per capture (10 
mM Tris pH 7.5, 500 mM LiCl, 0.5% Triton X-100, 0.2% sodium dodecyl sulphate, 0.1% 
sodium deoxycholate) supplemented with Protease Inhibitor Cocktail (EMD Millipore) and 
1000 U of Murine RNase Inhibitor (New England Biolabs).  We found the smaller the 
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volume used per sample, the more efficient the capture was downstream and thus the 
minimum volume needed to lyse cells should be optimized.  Samples were incubated for 10 
min on ice to allow lysis.  Following lysis, sample was passed through 20-gauge needle once 
and then 26-gauge needle 3-5 times to disrupt the pellet and shear genomic DNA.  In between 
passing the sample through the 26-gauge needle, the sample was sonicated on ice with a 
microtip set at 5W power for a total of 30 s in intermittent pulses (0.7 s on, 1.3 s off).  Samples 
were then mixed with twice the lysate volume of 1.5x LiCl/Urea Buffer (the final buffer 
contains 10 mM Tris pH 7.5, 500 mM LiCl, 0.5% Triton X-100, 0.2% SDS, 0.1% 
deoxycholate, 4 M urea). Lysates were incubated on ice for 10 min then cleared by 
centrifugation for 10 min at 4,000g. 
Pre-clearing lysate: BioMag streptavidin beads (Bang Laboratories Inc.) were first washed 
3x in 0.25-0.5ml of 500mM LiCl/4M Urea buffer (10 mM Tris pH 7.5, 500 mM LiCl, 0.5% 
Triton X-100, 0.2% SDS, 0.1% deoxycholate, 4 M urea).  50ul of beads were added to each 
sample and the samples were incubated at 37°C for 30 min with shaking.  Streptavidin beads 
were then magnetically separated from lysate samples using a magnet.  The beads used for 
preclearing lysate were discarded and the lysate sample was transferred to fresh tubes twice 
to remove all traces of magnetic beads.  Input for quality control experiments can be removed 
at this point.   
Hybridization, Capture of Probes and Elution of Associated Protein: Following pre-clearing, 
the biotinylated 90-mer DNA oligonucleotide probes specific for the RNA target of interest 
(vary per sample but ~5ul of 25uM per probe) were heat-denatured at 85°C for 3 min and 
then snap-cooled on ice.  Probes and pre-cleared lysate were mixed and incubated at 55°C 
with shaking for 2 h to hybridize probes to the capture target RNA.  500mL of washed 
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streptavidin beads (Bang Laboratories Inc.) were then added to each sample at 55°C with 
shaking for 30 mins.  Beads with captured hybrids were washed 6 times with LiCl/Urea 
Hybridization Buffer.  If needed, 1% of the beads can be removed for qPCR quality control 
experiment.  TRIzol reagent can be added directly to beads to elute RNA.  Beads were then 
resuspended in Benzonase Elution Buffer (20 mM Tris pH 8.0, 2 mM MgCl2, 0.05% NLS, 
0.5 mM TCEP) and 125 U of Benzonase nonspecific RNA/DNA nuclease was added.  
Incubation occurred for 1-2 h at 37°C.  Beads were then separated from the sample using a 
magnet.  Supernatant was collected.  Contaminant beads were removed by 5 rounds of 
magnetic separation on supernatant.  Protein was precipitated overnight at 4°C with 10% 
trichloroacetic acid (TCA). TCA treated protein elution samples were pelleted by 
centrifugation for 30 min at 20,000g, then washed with 1 ml cold acetone and recentrifuged. 
Final protein elution pellets were air dried to remove acetone, resuspended in fresh 8 M urea 
dissolved in 40 ml of 100 mM Tris-HCl pH 8.5, and stored at -20°C. 
Mass Spec Prep. and Analysis Performed as in McHugh et al. with few exceptions.  Instead 
of SILAC we label proteins at the mass spec prep step using TMT (Thermo).  After desalting 
on a Microm Bioresources C8 peptide MicroTrap column and lyophilization of peptide 
fraction, lyophilized protein pellets were resuspended in 100mM TEAB at a concentration 
of 1ug/ul.  We then added 1.64ul of TMT labelling reagent to each ug of sample.  The reaction 
was incubated for one hour at room temperature.  The reaction was quenched with 0.32ul of 
5% hydroxylamine per ug of protein used and incubated for 15 mins at room temperature.  
Following quenching, the samples were mixed, desalted as before, lyophilized, and mass 
spec was performed on Orbitrap Fusion mass spectrometer using a TMT instrument method 
as described in Liu et al (Liu et al., 2016). 
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Raw files were searched using MaxQuant (v. 1.5.3.30) against the UniProt mouse database 
(59550 sequences) and a contaminant database (248 sequences). TMT 6plex was selected as 
the quantitation method with a reporter mass tolerance of 0.3. Oxidation of methionine and 
protein N-terminal acetylation were variable modifications and carbamidomethylation of 
cysteine was fixed modification. A 1% protein and peptide false discovery rate as estimated 
by the target-decoy approach was used for identification. 
 
RNA Immunoprecipitation 
RNA immunoprecipitations were performed as previously described.  Between 5-10 
confluent 15 cm2 dishes of BMDMs per sample were stimulated with either 20ng/mL of 
TNFα for 30 minutes or 5ug/mL Poly(I:C) for 12 hours.  Following stimulation, proteins 
were cross-linked to DNA by adding formaldehyde directly to the media to a final 
concentration of 0.75%, with light shaking at room temperature for 10 mins.  To quench the 
crosslinking reaction, glycine to a final concentration of 125 mM was added to the media 
and incubated with shaking for 5 mins at room temp.  Media was then aspirated and cells 
were rinsed twice with 10 mL of cold PBS.  Following the second wash, cells were scraped 
into 10mL of PBS and spun down gently (5 min, 4°C, 1,000xg).  Final cell pellet was 
resuspended in 0.1-1mL of polysome lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM 
HEPES (pH 7.0), 0.5% NP40, 1 mM DTT, 100 U.ml RNase Inhibitor (NEB)) supplemented 
with Protease Inhibitor Cocktail (EMD Millipore).  At this point the mRNP lysate was frozen.  
If needed, passing the lysate through a small gauge needle can help with lysate.  Protein-G 
beads were pre-treated at 4°C with NT2 (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM 
MgCl2, 0.05% NP40) supplemented with 5% BSA to a final ratio of 1:5 for at least 1h before 
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use.  Appropriate amount of antibody per sample (optimized based on antibodyused but 
typically ~1-10ug) was added ot 250-500ul of bead/BSA slurry and incubated at 4°C.  
Following incubation, beads were spun down and washed with 1 ml of ice-cold NT2 buffer 
4–5 times.  Following final wash, beads were resuspended in 850ul of NT2 and supplemented 
with 200U of RNase inhibitor, 10 µl of 100 mM DTT and EDTA to 20 mM.  Frozen lysate 
was thawed and centrifuged at 15,000*g for 15 mins.  The cleared supernatant was removed 
and 100ul was added to the prepared beads.  Input removed at this step.  Beads and lysate 
were incubated for 4h at 4°C with mixing.  The beads were washed 4-5 times with ice-cold 
NT2 and then resuspended in 100ul of NT2 buffer.  4ul of 5M NaCl was added incubated 
with shaking at 65°C for 2 hours. NT2 buffer can also be supplemented with 30 µg of 
proteinase K to release the RNP component. RNA was isolated by adding TRIzol reagent 
(Ambion) as per the manufacturer’s instructions.  RNA was reverse transcribed and 
quantification was performed using TaqMan qPCR.   
 
Immunoblot 
BMDM samples were prepared as described previously.  BMDMs were stimulated with 
either TNFα or Poly(I:C) for the indicated period of time.  Cells extracts were collected using 
RIPA lysis buffer (Sigma cat: R0278-50ML), and were subjected to gel electrophoresis and 
transfer onto a nitrocellulose membrane.  pRroteins were analyzed by immunoblot using the 
following reagents:  anti-IRF7 (abcam, ab215326) and anti-beta Actin (Cell Signalling, 
13E5).  For nuclear fractionation, cells were scraped into subcellular fractionation buffer 
(20mM HEPES (pH 7.4), 10 mM KCl, 2 mM MgCl2, 1mM EDTA, 1 mM EGTA).  The cells 
were then passed through a 27-gauge needle 10 times, incubated on ice for 10 mins, and spun 
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down at 720xg for 5 min.  The pellet contained the nuclei, which was washed with 
fractionation buffer, passed through a 25-gauge needle 10 times, and centrifuged again at 
720xg for 10 mins.  The resulting pellet was resuspended in RIPA lysis buffer.  Equal 
amounts of proteins were analyzed by immunoblot using the following reagents:  anti-IRF7 
(Millipore, ABF130), anti-Lamin B1 HRP conjugate (Cell Signalling, D9V6H), and anti-
rabbit IgG HRP conjugate (Cell Signalling). 
 
Viral Plaque Assays 
Plaque assays were done one Vero cells.  2.5*105 vero cells were plated in a 12 well plate 
the night before infection.  Prior to infection, cells were checked to ensure confluence.  VSV 
was serially diluted and infected in 12 well plate for 1 h.  VSV was then removed and cells 
were layered carefully with DMEM supplemented with 2% FBS and 0.4% agarose.  Plate 
was incubated for 2 days, and then fixed with 10% formaldehyde, for 1 h to overnight.  
Finally, agarose plugs were removed carefully and cells were stained with crystal violet.  
 
VSV-GFP Infection Experiment 
BMDMs were grown as described above in 150mm dishes.  On day 8, following ~72 hours 
of puromycin treatment, media was removed and 10mL of PBS w/ 2mM EDTA was added.  
Cells were lightly scraped and 250,000 cells/well were replated in 12 well plates in BMDM 
media.  Cells were left for 12 hours to adhere.  Following adherence, VSV-GFP was added 
at the specified MOI for the specified amount of time.  Following the time-course, cells were 
lightly scraped, washed and spun down, and resuspended in PBS. Samples were analyzed on 
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a MACSQuant10 Flow Cytometry machine (Miltenyi).  Gating strategy depicted in Figure 
S7.  
 
VSV-GFP Viral Supernatant Experiment 
BMDMs were grown as described above in 150mm dishes.   On day 8, following ~72 hours 
of puromycin treatment, media was removed and 10mL of PBS w/ 2mM EDTA was added.  
Cells were lightly scraped and 400,000 cells/well were replated in 12 well plates in BMDM 
media.  Cells were left to adhere for 12 hours, before being infected at an MOI of 25 for 8 
hours.  Following infection, virus was removed and the cells were washed with PBS three 
times.  Then, 500ul of BMDM media (DMEM, 20% FBS, 30% L929 condition media, and 
1% Pen/Strep) was added to each well.  18 hours later, media was collected and stored at -
80°C.  To titer viral supernatant, Vero cells were plated in a 96-well plate at 30,000 cells per 
well in 90ul of D10 media.  12 hours after plating, 90ul supernatant was added to the 90ul of 
D10 at different dilutions.  PFU/mL was calculated from a standard curve with a virus of 
known concentration. 
 
Quantification and Statistical Analysis 
All statistical analysis was performed in Python (version 2.7.9).  Unless otherwise indicated 
in figure legends, statistical significance measurements were marked as follows: * denotes p 
< 0.05, ** denotes p < 0.01, *** denotes p < 0.001, and n.s. denotes not significant.  RNA-






Sequencing was performed on a HiSeq 2500 High Throughput Sequencer (Illumina).  Single-
end 50-mer reads were aligned using Tophat v2.1.1 (Kim et al., 2013).  Gene expression was 
determined using Cufflinks v2.2.1 and the FPKM (Fragments Per Kilobase Million) metric 
(Trapnell et al., 2010). 
 
Splicing Ratio and ΔSR Calculation 
A custom script was written in Python using the HTSeq (Anders et al., 2015) library to 
calculate Splicing Ratio. First, reads that map to an intron or exon feature are summed.  To 
map to a feature, reads must have >1 bp overlap with the feature.  If a read maps to more 
than one feature, such as in the case of a splice junction read, the read is split between the 
features.  SR is calculated by taking the length normalized number of reads that map to each 
intron, divided by the average length normalized number of exon reads plus the length 
normalized intron value.  When SR is equal to 0, this indicates a junction is completely 
spliced.  In contrast, large SR values indicate intron retention.  We use the SR value to 
calculate ΔSR, which is equal to SR(shBUD13) – SR(Ctl).  Values greater than 0 indicate 
the junction is more unspliced in the shBud13 sample, whereas values less than 0 indicate 
the junction is more unspliced in the Ctl sample.  For each stimulation (TNFα, Poly(I:C), and 
CpG), ΔSR was calculated for each individual junction of the Irf7 transcript.  Bar graphs 
represent the mean (error bars indicate s.d.) ΔSR for stimulated time-points (non-zero time-
points).  For the global analysis, in order for the ΔSR of a junction to be considered, it must 
pass through a number of filters.  To account for transcripts that are annotated in Ensembl 
version 67, but not expressed, we set an FPKM threshold of 15.  Further, a local normalized 
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read count threshold on the upstream/downstream exons was implemented to ensure a level 
of sequencing depth needed to get accurate splicing values.  To pass this threshold, the sum 
of the reads that map to the the upstream/downstream exons divided by the length of these 
exons must be ≥ 0.25.  
 
ISG and Genome-Wide Analysis 
ISGs used in Figures 4 E-H were selected based on induction 2 hours after in vivo IFNa 
injection (Mostafavi et al., 2016).  We classified ISGs to be any gene with a fold change ≥ 
3.5 following 2 hours of induction.  Intron RPKM was calculated using a custom python 
script with the HTSeq library.  In Figure 5a, transcripts from the 30 min. TNFα data-set that 
had a junction with a ΔSR value above 0.15 were sorted into an ‘increased IR’ category (ΔSR 
>0.15), whereas all other transcripts were sorted into an unaffected category (ΔSR <-0.15).  
The selected data-set is representative of all time-points from the TNFα, Poly(I:C) and CpG 
datasets.  A maximum entropy model was used to calculate 3’ and 5’ splice site strengths 
(Yeo and Burge, 2004).  To determine differences in 5’ splice site sequence for Bud13 
dependent junctions, the nine base pair sequence near the 5’ splice site junctions for junctions 
that had a ΔSR >0.15 was compared to all expressed junctions (FPKM>1).  The top Bud13 
dependent junctions were plotted based on the average ΔSR value across all time-points from 
the TNFα data-set (Figure 5D) as well as the Poly (I:C) data-set (Figure S5H).  Junctions that 
had a ΔSR value <0.15 in a time-point were filtered out in the TNFα data-set, while junctions 
that had a ΔSR value <0.15 in two time-points were filtered out in the Poly (I:C) data-set.  
The zero time-point was removd for the transcripts induced by the stimulant (Irf7 and Cd14).  
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For the comparison of alternative splicing events, rMATs (S. Shen et al., 2014) was used on 
the TNFα data-set.  Splicing events were deemed significant if p<0.05 and FDR<0.1 for all 
time-points.  SVMBPfinder was used to determine BP related features (BP strength and 
distance from BP to 3' splice site) (Corvelo et al., 2010). 
 
eCLIP 
Data for eCLIP experiments were downloaded from ENCODE Project Consortium 
(Consortium, 2012).  Analysis of eCLIP data is the same as has been described previously 
(Van Nostrand et al., 2016).  Fold change of eCLIP read density compared to input read 
density along a normalized intron was calculated using ngs.plot.(L. Shen et al., 2014)  Bud13 
dependent junctions were calculated using ΔSR.  In K562 cells, any junction that had a ΔSR 
> 0.1 for all pairwise comparison of replicates was considered Bud13 dependent.  In Hep G2, 
the ΔSR was lowered to 0.03.  Peaks were called using CLIPper (Lovci et al., 2013).  Peaks 
were deemed significant if they were >3-fold enriched and had p-value<10-5.  Peak locations 
were determined using a custom python script with the HTSeq library.  Enriched GO terms 
were determined using Seten (Budak et al., 2017). 
 
Data and Software Availability 
All next-generation sequencing data reported in this study is depsited in the Gene Expression 







Figure 1: Irf7 contains a weak intron that is retained following many forms of 
stimulation.  (A) Histogram of mapped reads corresponding to the TNFα-induced 
expression of Irf7.  The poorly spliced fourth intron is highlighted.  For all read density plots, 
reads are histogrammed in log10 scale and normalized to the maximum value across the 
stimulation.  (B) Comparison of Irf7 splice donor and acceptor sites in mice, rats, and 
humans.  (C-F) Histogram representing the intron length (C), intron GC content (D), flanking 
exon GC content (E), or 5’ splice site strength of introns of expressed in BMDMs.  Red 
represents location of Irf7 intron 4 (C, D, F) or upstream exon (E). Black line represents 
downstream exon (E). (G, H) Histogram of mapped reads corresponding to the IFNα (G) 
and poly(I:C) (H) induced expression of Irf7 focused on the slow splicing fourth intron. (I) 
Outline of Splicing Ratio (SR) metric. (J) Splicing ratio for all introns in Irf7 plotted against 
time stimulated with TNFα.   
 
Figure 2: RAP-MS and RIP identifies BUD13 as an RNA binding protein that interacts 
with Irf7 mRNA.  (A) Outline of the RAP-MS procedure used to identify RNA-binding 
proteins on transcritps of interest. (B)  TMT ratio (Irf7/Actb) for proteins identified as 
enriched on either Irf7 (TMT ratio >1) or ActB (TMT ratio <1) transcripts.  (C) RT-qPCR 
analysis of transcripts captured via RAP for Irf7 (blue) and ActB (gold) probes.  (D) RIP 
followed by RT-qPCR for Irf7 and Rpl32 in TNFα stimulated BMDMs.  Shown is the 
relative enrichment of transcripts captured in BUD13 RIP as compared to Rabbit IgG RIP. 
(E) Same as (d) except stimulation with poly(I:C).  Data are representative of two 
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independent experiments ((C-E), mean, error bars indicate s.d.). *P < 0.05, **P < 0.01 and 
***P < 0.001 (t-test).  
 
Figure 3: BUD13 knockdown leads to increased retention in the poorly splicing intron 
of Irf7.  (A) Histogram of mapped reads corresponding to the TNFα-induced expression of 
Irf7.  The poorly spliced fourth intron is highlighted.  shBUD13 samples are shown in green.  
Control samples are shown in grey. (B) ΔSRs calculated for each junction in the Irf7 
transcript for all stimulated time-points.  The ΔSR of intron 4 as compared to all other 
junctions is significant (Student’s t-test, p<0.001).  No other pairwise comparison is 
significant.  (C) Splicing gel from RNA extracted from BMDMS stimulated for 30 mins. 
TNFα (top).  Quantification of splicing gel (bottom).  (D) Irf7 FPKM fold change with 
respect to time stimulated.  shBUD13 is shown in green, control is shown in grey. Data is 
representative of two independent experiments (C) and is represented as mean (error bars 
indicate s.d.).  * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a 
Student’s t test. 
Figure 4: BUD13 knockdown alters the type I interferon response. (A) Histogram of 
mapped reads corresponding to the TNFα-induced expression of Irf7.  The poorly spliced 
fourth intron is highlighted.  shBUD13 samples are shown in blue. Control samples are 
shown in grey. (B) ΔSRs calculated for each junction in the Irf7 transcript for all stimulated 
time-points.  The ΔSR of intron 4 as compared to all other junctions is significant 
(Student’s t-test, p<0.001).  No other pairwise comparison is significant.  (C) Irf7 FPKM 
fold change with respect to time stimulated.  shBUD13 is shown in blue, control is shown 
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in grey.  (D) Immunoblot analysis of IRF7 protein following 720 mins. poly(I:C) 
stimulation (left).  Quantification relative to ActB (right). (E) Log2 expression fold change 
(shBUD13/control) for 119 ISGs in unstimulated BMDMs (median = 0.1655). (F) As in 
(E) for stimulated BMDMs (720 mins poly(I:C) (median = -0.1007). Wilcoxon rank-sum 
between (E) and (F), P< .001.  (G) Median log2 expression fold change (shBUD13/control) 
for ISGs in unstimulated BMDMs, and BMDMs stimulated with Poly(I:C) 15, 60, 240, 
720, and 1440 mins.  Bars represent 95% CI.  (Wilcoxon rank-sum, P< .001, for any of the 
‘early’ time-points (0, 15, 60 mins) compared to any of the ‘late’ time-points (240, 720, 
1440 mins). (H) RT-qPCR analysis of IFNα mRNA levels in unstimulated BMDMs and 
BMDMs stimulated with poly(I:C) for 720 mins and 1440 mins. (I) Same as (H) for IFNβ. 
(J) Nuclear fraction (top) and cytoplasmic fraction (bottom) histograms of mapped reads 
corresponding to the poly(I:C)-induced expression of Irf7 (720 mins). The poorly spliced 
fourth intron is highlighted.  shBUD13 samples are shown in blue.  Control samples are 
shown in grey. Nuclear ΔSR = 0.35. (K) Nuclear and cytoplasmic RPKM for Irf7 intron 4 
from fractionated BMDMs stimulated with poly(I:C).  (L) Cytoplasmic Irf7 FPKM for 
control (grey) and shBUD13 BMDMs stimulated with poly(I:C).  Data is representative of 
three (D) or four (H,I) independent experiments and is represented as mean (error bars 
indicate s.d.).  * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a 
Student’s t test.  Results are presented relative to those of Rpl32 (H,I). 
Figure 5: Global analysis of the role of BUD13. (A) Ranked bar chart showing genes with 
a junction most affected by BUD13 knock-down in all samples during TNFα stimulation.  
See S7 for histograms relating to most affected junctions. (B) Grouped bar chart depicting 
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the number of genes that have a single BUD13 affected junction vs. multiple BUD13 
affected junctions using three different ΔSR thresholds.  (C) Transcripts were classified as 
‘BUD13 dependent’ if they had a junction with a ΔSR. >0.15.  The log2 expression fold 
change (FPKM shBUD13/ FPKM control) for each gene represented by the transcripts in the 
‘BUD13 dependent’ category as well as all other genes is shown.  Median ‘increased IR’ = 
-0.5084.  Median ‘decreased IR’ = -0.2170.  (Wilcoxon rank-sum, P< .01).  (D)  Mean ΔSR. 
for junctions below the indicated threshold (x-axis) vs. mean ΔSR. for all junctions.  
Threshold applied for the 5’ splice site (blue) and the 3’ splice site (green). (E) 5’SS motif 
for all expressed junctions as compared to junctions that show retention upon Bud13 
knockdown (ΔSR. > 0.15). (F) Size of intron for introns retained upon BUD13 knockdown 
(ΔSR. > 0.15) (blue), in introns located in the same transcript as those affected by BUD13 
(green), and in introns from all expressed transcripts (orange). (G) Same as (F) for GC 
content.  (H) Flanking exon GC content for exons that flank introns retained upon 
BUD13 knockdown (ΔSR. > 0.15) (dark green) as compared to exons that flank introns from 
all expressed transcripts (light green).  (I) Distance from the branch point to the 3’ splice site 
for introns retained upon BUD13 knockdown (ΔSR. > 0.15) (dark blue) as compared to 
introns from all expressed transcripts (light blue).  (F-I) data from BMDM TNFα 
stimulation. Box plots show median (center line), interquartile range (box) and tenth and 
ninetieth percentiles.  *P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-Whitney U-test).  
Figure 6: BUD13 interacts primarily near the 3’ splice site of small, GC rich introns. 
(A) eCLIP-seq read density plots in K562 cells.  BUD13 density plot over all expressed 
junctions shown in blue (top), BUD13 density plot over BUD13 dependent junctions shown 
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in red (top). SF3B4 density plot over all expressed junctions shown in maroon (middle), and 
PRPF8 density plot over all expressed junctions is shown in green (bottom).  (B) Same as in 
(A) but for Hep G2 cells.  (C) BUD13 eCLIP-seq peak distribution.  Peaks fell within either 
intronic regions, intron-exon junctions, or exonic regions.  Peaks that fell within intron-exon 
junction were further classified as 5’ junction peaks or 3’ junction peaks (bottom).  (D) Same 
as (C) but for Hep G2.  (E)  Size of all introns in expressed transcripts for the given cell line 
(dark blue) vs size of introns with overlapping eCLIP peak (maroon).  Shown in K562 (left) 
and Hep G2 (right) cells.  Box plots show median (center line), interquartile range (box) and 
tenth and ninetieth percentiles (whiskers).  *P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-
Whitney U-test). (F) Same as (E) for GC content.  (G) GO terms (biological process) 
enriched among BUD13 eCLIP peaks in K562(dark blue) and Hep G2 (maroon) cells. 
Figure 7: BUD13 knockdown alters the BMDM response to VSV. (A) RT-qPCR analysis 
of Irf7 mRNA levels in infected control or shBUD13 BMDMs stimulated with VSV (MOI 
5) across 24 hours.  (B) Same as in (A) except stimulated at an MOI of 10. Results are 
presented relative to those of Rpl32. (C) PFU/mL for viral supernatant from infected 
shBUD13 (blue), control (red), shBUD13 with Irf7 overexpression (yellow), or control with 
Irf7 overexpression (maroon) BMDMs.   Data is representative of two (A, B) or three 
independent experiments (C) and is shown as mean (error bars indicate s.d.). * denotes p < 
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Figure S1: Splicing Ratios across all junctions in Irf7.  Related to Figure 1.  Splicing 
ratios calculated for all junctions in the most abundant transcript of Irf7.  Color represents 
time-point indicated in legend.  (A) Poly(I:C) (B) IFNα. 
Figure S2: shBUD13 knocks down BUD13 protein and mRNA.  Related to Figure 3. 
(A) Immunoblot analysis of BUD13 in BMDMs infected with control or shBUD13.  ActB 
serves as loading control.  (B) qRT-PCR analysis of Bud13 mRNA in BMDMs infected with 
control or shBUD13.  (C) Immunoblot analysis of IRF7 protein following 120 mins. TNFα 
stimulation.  (D-F) FPKM fold change with respect to time stimulated (C) Zfp36, (D) IκBϵ, 
and (E) CD83.  shBUD13 is shown in green, control is shown in grey. Data is representative 
of two individual experiments (A, B) and is shown as mean (error bars indicate s.d.) (B). 
*P < 0.05, **P < 0.01 and ***P < 0.001.  
Figure S3: Irf7 Intron 4 is the most BUD13 knockdown affected junction of all ISGs. 
Related to Figure 4. (A) Normalized levels of spliced vs. unspliced intron 4 in control and 
shBUD13 BMDMs as measure through quantitative RT-qPCR.  (B) Normalized FPKM 
expression levels in shBUD13 and control samples at 720 mins poly(I:C) stimulation for 
select ISGs). (C) ΔSR was calculated at 720 mins of poly(I:C) stimulation for each ISG 
junction that passed the transcript and local read count threshold (see methods).  Mean ΔSR 
= 0.002, Median ΔSR = 0. (D) Immunoblot analysis of Irf7 protein after nuclear fractionation 
from BMDMs left untreated (UT) or treated with poly(I:C) (PIC) or CpG for 12h. Lamin B1 
serves as loading control.  
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Figure S4: BUD13 knockdown alters the type I interferon response in response to CpG. 
(A) Histogram of mapped reads corresponding to the CpG-induced expression of Irf7.  The 
poorly spliced fourth intron is highlighted.  shBUD13 samples are shown in pink.  Control 
samples are shown in grey. (B) Irf7 FPKM fold change with respect to time stimulated.  
shBUD13 is shown in pink, control is shown in grey. (C) RT-qPCR analysis of IFNα mRNA 
levels in unstimulated BMDMs and BMDMs stimulated with CpG for 720 and 1440 mins.  
(D) Log2 expression fold change (shBUD13/Control) for 119 ISGs (selected based on 
upregulation in response to IFNα) in unstimulated BMDMs (median = -0.2442). (E) As in 
(D) for stimulated BMDMs (720 mins CpG (median = -0.4776). Wilcoxon rank-sum 
between (D) and (E), P< .001.  (F) Ratio of cytoplasmic FPKM levels to cytoplasmic and 
nuclear FPKM levels for transcripts that are primarily nuclear (Malat1, Neat1, Xist, U2; left), 
and primarily cytoplasmic (Rpl32, Rps5, Actb, Rpl5; right) (BMDMs – 720 mins poly(I:C) 
stimulation). (G)  Nuclear ΔSR calculated for each junction in the Irf7 transcript. Unless 
indicated, comparison of intron 4 ΔSR to any other junction is significant (Student’s t-test, 
p<0.001).  No other pairwise comparison is significant.  Data is represented as mean (error 
bars indicate s.d.).  * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using 
a Student’s t test.  Results are presented relative to those of Rpl32. 
 
Figure S5: Supplemental global analysis of BUD13.  Related to Figure 5 and 6. (A) Size 
of intron for introns retained upon BUD13 knockdown (ΔSR. > 0.15) (blue), in introns 
located in the same transcript as those affected by BUD13 (green), and in introns from all 
expressed transcripts (orange). (B) Same as (A) for GC content.  (C) Flanking exon GC 
content for exons that flank introns retained upon BUD13 knockdown (ΔSR. > 0.15) (dark 
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green) as compared to exons that flank introns from all expressed transcripts (light green).  
(D) Distance from the branch point to the 3’ splice site for introns retained upon BUD13 
knockdown (ΔSR. > 0.15) (dark blue) as compared to introns from all expressed transcripts 
(light blue).  (A-D) data from BMDM poly(I:C) stimulation. (E) Branch point score for 
introns retained upon Bud13 knockdown (ΔSR. > 0.15) (beige) as compared to introns from 
all expressed transcripts (dark brown) in TNFα stimulated BMDMs.  (F) Same as (E) but for 
poly(I:C) stimulated BMDMs.  (G) Significant number of alternative splicing events across 
the TNFα time-course as calculated by rMATs.  (H)  Ranked bar chart showing genes with 
a junction most affected by BUD13 knock-down in all samples during PIC stimulation.  (I) 
Box plot showing the number of retention events across replicates at the indicated ΔSR.  Box 
plots show median (center line), interquartile range (box) and tenth and ninetieth percentiles.  
*P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-Whitney U-test).   
 
Figure S6: BUD13 knockdown alters the BMDM infection via VSV.  Related to Figure 
7.  (A) FSC/SSC plot showing the gating of live BMDMs in an uninfected control sample 
and the subsequent threshold used to calculate infectivity.  (B) Same as in (A) but for a 
control sample infected with VSV-GFP for 12 hours.  (C) Percent of live cells infected with 
VSV-GFP (MOI 10) in both control and shBUD13 BMDMs across a 24-hour time-course.  
(D) Percent of live cells infected in both control and shBUD13 BMDMs at 12 hours across 
a range of VSV-GFP MOIs.  Data is representative of three (C, D) independent experiments 
and is represented as mean (error bars indicate s.d.).  * denotes p < 0.05, ** denotes p < 0.01, 




Figure S7: Knockdown of other RES complex proteins. Related to Figure 4.  (A) 
Bargraph indicating knockdown efficiency for RBMX2 shRNA (green) and SNIP1 shRNA 
(orange) as compared to BUD13 shRNA (blue).  (B) ΔSRs calculated for each junction in 
the Irf7 transcript for shBUD13 (blue), shRBMX2 (green) and shSNIP1 (orange).  The 
shBUD13 data is from figure 4 and is shown for perspective.  Comparison of intron ΔSR at 
intron 4 to all other junctions is significant (Student’s t-test, p<0.001).  No other pairwise 
comparison is significant for shBUD13.  No pairwise comparison is significant for other 
knockdown constructs. (C) Box plot showing the number of retention events across 
replicates at the indicated ΔSR for shBUD13 (blue), shRBMX2 (green), and shSNIP1 
(orange). 
 
Supplemental Table S1: shRNA Sequences. Related to STAR Methods. 
Supplemental Table S2: List of Irf7/ActB Associated Proteins Detected with RAP-MS. 
Related to Figure 2 
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Alternative Splicing Coupled with NMD Acts to Mitigate OAS1 Antiviral 
Activity 
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At the heart of an innate immune response lies a tightly regulated gene expression program.  
This precise regulation is crucial because small changes can shift the balance from protective 
to destructive immunity.  Here we identify a frequently used alternative splice site in the gene 
oligoadenylate synthetase 1g (Oas1g), a key component of the 2-5A antiviral system.  Usage 
of this splice site leads to the generation of a transcript subject to decay, and removal of the 
site leads to increased expression of Oas1g and an improved antiviral response.  However, 
removal of the splice site also leads to an increase in apoptotic cell death, suggesting this 
splicing event exists as a compromise between the pathogen protective benefits and collateral 
damage associated with OAS1g activity.  Across the innate immune response, we show 
similar alternative splicing events coupled with decay are widespread and represent a 























Central to an inflammatory response is a robust and coordinated gene expression program.  
Precise regulation of this gene expression program is essential because small alterations can 
shift the balance from protective to destructive immunity1.  While transcription and protein 
turnover are the best-examined areas of gene expression regulation2–5, a variety of post-
transcriptional mechanisms have emerged that play a role in the fine-tuning of an 
inflammatory response.  Well-studied examples include mRNA stabilization6, mRNA 
deadenylation7, and microRNA regulation8.   
More recently, the wealth of transcriptomic data generated over the last decade has 
shed light on the widespread nature of alternative mRNA splicing of mammalian genes.  
While most mammalian genes exhibit alternative splicing9,10, not all of the produced 
transcripts encode functional proteins. It is true that alternative splicing can act to increase 
proteomic diversity; however, it can also generate unproductive isoforms that incorporate a 
premature termination codon (PTC), thus subjecting the transcript to either cytoplasmic 
NMD decay11.  Coupling of alternative splicing to NMD decay (AS-NMD) provides cells 
with a mode of downregulation of expression of a given gene.  It has been estimated that 10-
30% of mammalian genes may be regulated post-transcriptionally, potentially in a context-
specific manner, through AS-NMD12–15. 
While several AS-NMD events have been identified and have been shown to play an 
important role in a variety of biological processes, most notably the autoregulation of splicing 
factor genes15,16, little is known with respect to the role of AS-NMD during the finely-tuned 
inflammatory response.  Here we identify a frequently used unproductive splicing event in 
oligoadenylate synthetase 1g (Oas1g), an important murine anti-viral response factor.  Upon 
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binding viral dsRNA, OAS1g acts to convert ATP into 2-5 linked oligoadenylates (2-5A), 
which in turn activate RNase L.  Although humans have a single Oas1 gene, in mice the 
Oas1 gene locus underwent a series of duplication events leading to the existence of eight 
Oas1 paralogues.  However, only OAS1a and OAS1g have been shown to be enzymatically 
active17,18.  Activated RNase L degrades viral RNA, in turn inhibiting viral replication and 
propagation19.  Removal of the Oas1g alternative splice site in a murine macrophage cell line 
led to increased expression of Oas1g, both in stimulated and unstimulated conditions.  
Further, this increased expression of Oas1g improved the ability of macrophages that lack 
the unproductive splice site to withstand infection with Encephalomyocarditis virus 
(EMCV).  However, removal of the Oas1g alternative splice site led to an increase in 
apoptotic cell death in uninfected cells, a finding consistent with the idea that activation of 
the 2-5A system can be detrimental to host fitness20–22.  Beyond Oas1g, AS-NMD events 
were found in a number of other important transcripts involved with the innate immune 
response.  Thus, evolution of splice sites in such transcripts, with a consequent dampening 
of gene output, is a means of mitigating what might otherwise be an unchecked or 
inappropriately scaled response. 
 
Results 
Oas1g has a Frequent AS-NMD Event  
AS events have the potential to generate both productive isoforms coding for functional 
proteins as well as unproductive isoforms subject to degradation (Figure 1A).  The latter 
allows for the use of AS as a post-transcriptional mechanism of gene-expression regulation.  
To investigate the extent to which unproductive splicing acts as a post-transcriptional 
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regulator of gene expression during inflammation, we analyzed nuclear fractionation RNA-
sequencing data from mouse bone marrow-derived macrophages (BMDMs) stimulated with 
the TLR3 agonist poly(I:C) for up to 12 hrs23.  Activation of TLR3 leads to activation of 
interferon regulator factors, production of interferon-α and β, and induction of a type I 
interferon response24.  From this data, we identified frequent usage of an alternative 5’ splice 
site at the third junction of Oas1g (Figure 1B).  In each time-point, this alternative 
“unproductive” splice site is frequently selected over the consensus “productive” splice site 
(Figure 1C, left).  This is evident by simply comparing the number of reads that map across 
the two different junctions, as well as through the use of the computational program MISO, 
which utilizes a probabilistic framework to estimate the expression of alternatively spliced 
isoforms25 (Figure 1C, right).  The expression metric is represented by the value Percent 
Spliced In (PSI; φ), which is an estimate of the fraction of transcripts that utilize the 
alternative splice site.  Of interest was the strength of the productive and unproductive splice 
site, which can be quantified using a maximum entropy model26.  We find the productive and 
unproductive 5’ splice sites are similar in strength, and are fairly strong with respect to all 
expressed junctions (Figure S1). 
Next we looked at this alternative splicing event in the context of all expressed 
junctions. To do this, we calculated the alternative junction usage at each expressed junction 
from the BMDM data-set stimulated with poly(I:C) for 4 hours (Figure 1D, see methods).  
From this junction-centric viewpoint, the sequencing data supports the conclusion that most 
expressed junctions splice with high fidelity (Figure 1E).  Still, there is some alternative 
junction usage, which can be attributed to both regulated AS events as well as splicing noise.  
With respect to the alternatively spliced junction of Oas1g, it ranks among the top percentile 
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of alternative junction usage, supporting the conclusion that this AS event is among the most 
frequently utilized in poly(I:C) stimulated BMDMs (Figure 1E).   
 
Removal of Alternative Splice Site Alters Oas1g Expression and Macrophage Response 
to EMCV. 
In order to explore the effect of this alternative splicing event on Oas1g expression, and 
correspondingly the antiviral response, we used clustered regularly interspaced short 
palindromic repeats (CRISPR)–CRISPR-associated protein-9 nuclease (Cas9) technology to 
engineer murine RAW 264.7 cell lines devoid of this unproductive splice site (Figure 2A).  
In parallel, cell lines expressing Cas9 and a non-targeting guide were generated.  We selected 
seven clones that had the splice site removed in both alleles, which we deem as “fixed” clones 
(Figure 2B, S2).  RT-PCR upon stimulation with poly(I:C) both confirmed alternative splice 
site usage in control populations, and showed forced productive splicing in these fixed clones 
(Figure 2C). 
To determine what effect this forced productive splicing has on Oas1g expression, 
we used Taqman qPCR to monitor levels of Oas1g in both unstimulated and stimulated (8 
hrs poly(I:C)) conditions.  In each case, the engineered lines lacking the unproductive Oas1g 
splice site had significantly higher levels of expression, presumably due to lack of AS-NMD 
associated with selection of the unproductive splice site (Figure 2D).  Of interest, levels of 
Oas1g in unstimulated Oas1g splice site engineered cells were similar to levels of Oas1g in 
stimulated control cells.  Next, to determine the effect of removal of the unproductive splice 
site with respect to the anti-viral response, we used EMCV to infect both groups of 
macrophages.  EMCV is a (+)ssRNA member of the Picornaviridae family that replicate 
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through partially dsRNA intermediates27.  Infection has been shown to cause accumulation 
of 2-5A, and viral replication is sensitive to the OAS/RNase L pathway20,28.  As 
oligoadenylate synthetases bind viral dsRNA, the RNA activators in EMCV-infected cells 
are believed to be the viral replicative intermediates19.  Upon 18 hrs of infection with EMCV, 
we again observed significantly higher levels of Oas1g expression in the engineered lines 
lacking the unproductive Oas1g splice site.  Using qPCR to measure levels of EMCV 
following 18 hrs of infection, we found the engineered lines controlled viral replication more 
efficiently than the control lines.  Thus, we conclude that forced productive splicing of Oas1g 
improves the antiviral defense through increased expression of Oas1g.  Next, as activation 
of the 2-5A system can affect apoptosis in host cells29, we were interested in determining 
whether removal of the unproductive Oas1g splice site altered the levels of apoptotic cells.  
These cells were detected with annexin V, which binds to phosphatidylserine exposed on the 
outer leaflet of cells undergoing apoptosis.  We observed ~2 fold increase in the fraction of 
cells positive for annexin V in the engineered lines lacking the unproductive Oas1g splice 
site as compared to the control cells (Figure 2G) in unstimulated conditions.  We conclude 
that the increased Oas1g observed with the removal of the unproductive splice site has the 
effect of increasing levels of apoptosis in a cell population.  
Of note, the other enzymatically active member of the murine Oas1 family, Oas1a, 
has a highly homologous junction with an identical unproductive splice site.  However, 
despite nearly complete similarity of sequence at and nearby this splice-site (Figure S3A), it 
is used less frequently than that of Oas1g (Figure S3B-D).  Because of this similarity, our 
guide targeted to the unproductive splice site of Oas1g also cut at Oas1a (Figure S4), and 
genotyping confirmed all selected clones deleted the Oas1a unproductive splice site in 
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addition to the Oas1g unproductive splice site.  Again, RT-PCR upon stimulation with 
poly(I:C) confirmed alternative splice site usage in control populations, and showed forced 
productive splicing in edited clones (Figure S3C).  To determine what effect this forced 
productive splicing has on Oas1a expression, we again used Taqman qPCR to monitor levels 
of Oas1a in both unstimulated and stimulated (8 hrs poly(I:C)) conditions.  In this case, we 
found that while the mean expression of Oas1a in both unstimulated and stimulated 
conditions was greater in non-engineered clones, the effect lacked significance (Figure S3D).  
We hypothesize the dampened effect with respect to Oas1a as compared to Oas1g is likely 
due to decreased usage of the unproductive splice site to begin with, but also note that the 
small differences observed in Oas1a expression levels could play a role in the 
aforementioned antiviral and apoptosis effects.   
 
A Similar AS-NMD Event Occurs in Human Monocytes 
Human Oas1 differs quite significantly from the mouse Oas1 paralogues, a finding that is 
perhaps not surprising given the volatile evolutionary history of the gene30–32.  The human 
Oas1 orthologue contains six exons, and alternative splicing gives rise to five isoforms (p42, 
p44, p46, p48, and p52) which differ at the C-terminal region.  Genetic variation that alters 
isoform abundance has been shown to lead to altered OAS1 activity and further, viral 
susceptibility33,34.  There exists a single G/A SNP in the OAS1 exon 6 splice-acceptor 
(rs10774671) that accounts for some of this variability.  Those with the G allele 
predominantly produce p46, while the A allele leads to production of p42, p44, p48, and p52. 
The p46 isoform has been shown to have increased activity, an effect mediated at least in 
part by defects in protein accumulation of the other alleles22,34,35.  
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However, in addition to the productive splicing events that lead to the generation of 
multiple isoforms, we also find a previously unreported unproductive splicing event at the 
third splice junction of Oas1.  Human monocytes consistently and frequently use an 
alternative splice site that leads to an NMD substrate (Figure 3B). This 3’ alternative splice 
both shifts the frame of the transcript and incorporates a PTC.  While this alternative splice 
site is used less frequently than the one found in murine Oas1g, it is worth noting that the 
human sequencing samples are derived from whole cell RNA as compared to nuclear RNA.  
As such, the fraction of human Oas1 transcripts that utilize the unproductive splice site  due 
to efficient degradation of transcripts targeted by the NMD decay machinery in the 
cytoplasm.  Interestingly enough, while this splice site is used frequently in a variety of 
stimuli, frequency of usage does differ with the cell-type and stimulation.  Monocytes 
stimulated with LPS use the alternative splice site much more frequently as compared to HIV 
infected CD4+ T cells (Figure 3B, C).  This points to stimulation and/or cell-type specific 
regulation of this splicing event.  Regardless, this AS-NMD, coupled with the altered activity 
from productive splicing events, supports the conclusion that despite differences between 
human Oas1 and mouse Oas1g, human Oas1 is extensively regulated at the post-
transcriptional level.  
 
AS-NMD Events Are Common in Transcripts Related to Innate Immunity 
While Oas1g contained one of the most frequently used AS-NMD events, it was not the only 
AS-NMD event found in genes related to the innate immune response.  For example, in 
nuclear fractionation RNA-sequencing data from mouse BMDMs stimulated with poly(I:C), 
we found significantly utilized skipped exon events that led to a frameshift and incorporation 
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of a PTC in the important inflammatory transcripts Mx1, IKKε, and Oasl2  (Figure 4A-C).  
In each case, the event is utilized in all, or nearly all of the sequenced time-points   These 
events were confirmed in a macrophage cell line with RT-PCR upon stimulation with 
poly(I:C) for 4, 8, and 12 hours (Figure 4E-F).  To classify AS-NMD events globally, we 
utilized the tool SplAdder to predict and quantify AS events supported by an input sample36.  
A stringent confidence criteria was required to avoid including AS events derived from 
splicing noise (see methods).  Then, a custom Python script was used to select only events 
that led to frameshifts and/or PTC inclusion.  Among the list of AS-NMD events, as 
compared to a background of expressed genes, we observed significant enrichment for GO 
terms associated with the innate immune response (Figure 4G).  With respect to the viral 
pathogen response, which is tasked with limiting viral replication through degradation of 
viral (as well as non-viral) mRNA and establishment of a cellular antiviral state, a host of 
factors involved with the response contain AS-NMD events identified here or in other 
published work23 (Figure 4H). 
 
Discussion 
The robust and coordinated gene expression program involved in the defense against 
pathogens requires extraordinarily tight regulation.  In this study, we sought to shed light on 
the role of AS-NMD in this regulation.  We identified a frequently used unproductive 
splicing event in Oas1g, an important murine anti-viral response factor, and show that forced 
productive splicing leads to increased Oas1g expression and further, an increased ability to 
clear virus.  Additionally, we identify a number of other examples of unproductive splicing 
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events in the innate immune response which could subject the corresponding transcript to 
decay via the NMD pathway.   
With respect to Oas1g, it is fair to ask what benefit such an alternative splicing event 
offers?  The alternative splice site mediating this AS-NMD event is of comparable strength 
to the consensus 5’ splice site (Figure S1).  If possession of the greatest pathogen defense 
were the only goal of an organism, it seems unlikely this splice site would be retained.  
However, while pathogen defense systems can provide a protective benefit, they also can 
cause collateral damage to a host.  With respect to Oas1, its pathogen defense effects are 
repeatedly forfeited by a host due to the fact its activity can be so detrimental22,37.  This is 
exemplified by the surprisingly high frequency of loss-of-function mutations in primates22, 
and the fact OAS1 activity has been completely lost in several animal lineages, including 
teleost fish and insects37.  Moreover, while mice deficient for RNase L, the downstream 
effector of Oas1 in the 2-5A system, exhibit susceptibility to viral infection20, in the absence 
of infection they display significantly increased longevity21.  Given the fact that host RNAs 
have been shown to be able to activate OAS enzymes, its reasonable to hypothesize that the 
longevity effect is mediated, at least in part, by chronic 2-5A production22,38–40.  With respect 
to the AS-NMD event we observed in Oas1g, we found removal of the unproductive splice 
site significantly increased the number of cells undergoing apoptosis.  From this, it stands to 
reason that removal of the unproductive splice site, while improving the ability to limit viral 
infection, could negatively impact host fitness.  In turn, we believe this splice site represents 
a compromise between the pathogen protective benefits and collateral damage associated 
with OAS1g activity. 
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A second question has to do with the manner with which this mitigation occurs.    
Innately, regulation at the post-transcriptional level through AS-NMD seems appears 
inefficient.  Why spend the resources to transcribe a transcript if it is destined for 
degradation?    For one, the very fact introns exist and are transient in nature argues against 
the idea that the cost of transcription is prohibitive41.  A significant majority of transcribed 
sequence (~90% in humans42) is spliced and discarded.  Additionally, it is well understood 
that transcriptional regulation is largely a cooperative venture43, epitomized by complexes 
like the interferon-β (IFN-β) enhanceosome44.  As transcriptional regulation is not simply 
one protein interacting with one DNA sequence, but instead a multitude of proteins 
interacting with a host of other proteins and a variety of DNA sequences, it is quite possible 
that once transcriptional control has been placed on a system, changing it quantitatively is 
difficult.  Thus, secondary mechanisms are needed to fine-tune the gene expression levels of 
select transcripts.  As such, we argue the fine-tuning capabilities inherent to splicing based 
post-transcriptional regulation far outweigh the cellular cost of additional transcription, 
especially in the context of a tightly regulated gene expression program like inflammation. 
It remains unknown whether the AS-NMD event in Oas1g is regulated by an external 
input or whether a constant fraction of transcripts is discarded.  While we do see a trend 
whereby increases in stimulation time accompany decreases in φ (Fig. 1C), in essence 
arguing this AS-NMD event acts as a break released upon Oas1g induction, we are hesitant 
to draw such a conclusion without both increased sequencing depth at Oas1g and more 
sequencing time-points.  Regardless, the fact that the alternative splice site for Oas1g and 
Oas1a is identical in sequence, and further both junctions are nearly identical, strongly 
supports the idea that trans-acting proteins might affect the process.  Newly developed 
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methods like RAP-MS45 and ChIRP46, which identify RNA binding proteins bound to RNAs 
of interest, could help discover interactions that have the ability to affect splice site selection. 
In summary, we found a frequently used AS-NMD event in Oas1g.  When the splice site that 
mediates this event is removed, we observed increased expression of Oas1g and an improved 
antiviral response.  A similar AS-NMD event was found in human Oas1.  Indeed, genetic 
variation that dampens OAS1 activity in humans has been shown to lead to susceptibility to 
viral infection, particularly to West Nile virus33 and Epstein Barr virus34.  Forced productive 
splicing using an antisense oligonucleotide could limit viral propagation and thus, has a 
potential therapeutic role in the treatment of infection.  Similar unproductive splicing events 
were found throughout the innate immune response.  While future studies should seek to 
understand the functional significance of individual events, this form of unproductive 
splicing represents a previously underappreciated mechanism of gene expression regulation 
in innate immunity. 
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Figure 1. Oas1g has a Frequent AS-NMD Event. (A) A schematic depiction an alternative 
splicing event leading to either a productive isoform destined for translation or an 
unproductive isoform destined for degradation.  (B) Sashimi plot for the entire gene body of 
Oas1g from BMDMs stimulated with poly(I:C) for 12 hrs.  Oas1g is a negative strand gene 
and is depicted right to left.  (C) (left) Sashimi plots centered at the third junction of Oas1g 
from BMDMs stimulated with poly(I:C) for 0, 1, 4, 8, and 12 hrs. (right) φ estimates (red 
line), as well as confidence intervals over estimates (histogram) for each time point.  (D) 
Schematic representation of the alternative junction usage calculation.  (E)  Pie chart 
representing alternative junction usage for all expressed junctions upon 4 hrs. of poly(I:C) 
stimulation.  The slice including the alternatively spliced third junction of Oas1g is depicted 
by the arrow.   
 
Figure 2. Removal of Alternative Splice Site Alters Oas1g Expression and Macrophage 
Response to EMCV. (A) Schematic representation of the two alternative splice isoforms, 
and the gRNA/Cas9 targeting of the alternative splice site. (B) Sanger sequencing gDNA 
from a control sample (top) and an Oas1 SS KO sample (bottom).  Sequencing is oriented 
such that the negative strand runs left to right.  The alternative splice site is represented by 
the yellow highlighted region.  (C) RT-PCR upon stimulation with poly(I:C) confirming 
alternative splice site usage in control populations and forced productive splicing in fixed 
clones.  (D)  RT-qPCR analysis of Oas1g mRNA levels in unstimulated and stimulated (8 
hrs poly(I:C)) macrophages.  Control samples are represented in light blue, SS KO clones 
are represented in dark blue.  (E)  RT-qPCR analysis of Oas1g mRNA levels in EMCV 
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infected (18 hrs) macrophages.  Control samples are represented in light blue, SS KO clones 
are represented in dark blue.  (F)  RT-qPCR measurement of EMCV viral load following 18 
hrs of infection at 1 MOI.  Control samples are represented in light blue, SS KO clones are 
represented in dark blue.  (G)  Annexin V staining for apoptotic cells under unstimulated 
conditions.  Control samples are represented in light blue, SS KO clones are represented in 
dark blue.  Data is representative of two independent experiments (D-G) and is shown as 
mean (error bars indicate SEM). * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p 
< 0.001 using a Student’s t test.  Results are presented relative to those of Rpl32 (D-F). 
 
Figure 3. A Similar AS-NMD Event Occurs in Human Macrophages.  (A) Depiction of 
the mRNA splice isoforms found in human Oas1.  There exists a single G/A SNP in the 
OAS1 exon 6 splice-acceptor (rs10774671), with the G variant producing the more active 
p46 isoform.  (B) Sashimi plots for an AS-NMD event identified in exon 3 of human Oas1 
from human monocytes stimulated with LPS for 0, 1 and 6 hrs.  (C) Same as (B) but for 
patient derived HIV infected CD4+ T cells. 
 
Figure 4. AS-NMD Events Are Common in Transcripts Related to Innate Immunity.  
(A) Sashimi plots for an AS-NMD event identified in Mx1 from BMDMs stimulated with 
poly(I:C) for 0, 1, 4, 8, and 12 hrs.  (B) Same as (A) for IKKε.  (C) Same as (A) for Oasl2.  
(D) RT-PCR of Mx1 upon stimulation with poly(I:C) for 4, 8, and 12 hrs.  (E) Same as (D) 
for IKKε.  (F) Same as (D) for Oasl2 (G) GO terms enriched for AS-NMD events, as 
compared to a background of expressed genes.  (H) Schematic representation of major 
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pathways in the viral pathogen response.  Red arrows are shown above factors containing 














































Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, David Baltimore. 
 
Experimental Model and Subject Detail 
Animals 
The California Institute of Technology Institutional Animal Care and Use Committee 
approved all experiments.  Bone marrow derived macrophages were isolated from mixed-
sex C57BL/6 mice and cultured and stimulated as previously described23. 
 
Cell Culture 
human embryonic kidney cells (HEK293T) were cultured in DMEM supplemented 
with 10% FBS. All cell lines were maintained at 37°C.  Human embryonic kindey cells 
(HEK293T) from ATCC were cultured in DMEM supplemented with 10% FBS and 1% 
Pen/Strep.  RAW 264.7 murine macrophages from ATCC were cultured in DMEM 





Total RNA was purified from BMDMs using TRIzol reagent (Ambion) as per the 
manufacturer’s instructions.  Genomic DNA in RNA purifications was eliminated through 
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treatment with Turbo DNase (Thermo Fisher Scientific) for 30 min at 37°C.  RT reactions 
were performed in 20µL (20mM DTT, 2X ProtoScript II Reverse Transcriptase Reaction 
Buffer (NEB), 1mM dNTPs, 40U Murine RNAse Inhibitor (NEB), and 200U ProtoScript II 
(NEB) Reverse Transcriptase) with 500-1000ng RNA. Reaction incubated in thermocycler 
with the following program: 1. 42°C for 60min, 2. 65°C for 20min. 
 
RT-PCR of Splice Isoforms 
Total RNA was isolated using Tri reagent solution and digested with DNase I 
(Invitrogen). RT reactions were performed in 20µL (20mM DTT, 2X ProtoScript II Reverse 
Transcriptase Reaction Buffer (NEB), 1mM dNTPs, 40U Murine RNAse Inhibitor (NEB), 
and 200U ProtoScript II (NEB) Reverse Transcriptase) with 500-1000ng RNA. Reaction 
incubated in thermocycler with the following program: 1. 42°C for 60min, 2. 65°C for 20min.  
PCR was performed using Q5 Hot Start High-Fidelity DNA Polymerase (NEB) and gene 
specific primers.  
 
CRISPR Experiments 
RAW 264.7 cell lines were grown in individual 10cm plates.  20,000 cells were plated in a 
cell well plate and left overnight to adhere.  Following adherence, lentvirus expressing Cas9 
and either the Oas1a/g guide or a scramble control guide was added to the cells.  48 hours 
later, infected cells were selected with puromycin, which was added at a concentration of 
3.75ug/mL.  Following 72 hours of selection, cells infected with the Oas1a/g guide were 
single-cell plated in 96 well plates.  Clones were passed to 6-well plates following 5 days of 
growth, at which point genotyping was performed.  Cells infected with the scramble control 
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guide were passaged as a bulk infected population, with independent biological replicates 
representing cells independently infected and puromycin selected. 
  
Poly(I:C) Stimulations 
RAW 264.7 cell lines were grown in individual 10cm plates.  12 hours prior to infection cells 
were counted and plated at a density of 350,000 cells/well in 6 well plate.  Following 
adherence, 5ug/mL of Poly(I:C) (Sigma) was added.  Following the infection, cells were 
lysed in TRIzol.  Viral RNA was quantified as described above.  Cellular RNA was 
quantified as described above.  
 
EMCV Infection Experiment 
RAW 264.7 cell lines were grown in individual 10cm plates.  12 hours prior to infection, 
cells were counted and plated at a density of 350,000 cells/well in 6 well plate.  Following 
adherence, EMCV was added at the specified MOI for the specified amount of time.  
Following the infection, cells were lysed in TRIzol.  Cellular and viral RNA was quantified 
as described above.   
 
Annexin V Experiment 
RAW 264.7 cell lines were grown in individual 10cm plates.  12 hours prior to infection, 
cells were counted and plated at a density of 125,000 cells/well in 12 well plate.  24 hours 
after plating, cells were stained with Annexin V APC Ready Flow Conjugate (Thermo 
Fischer).  Samples were analyzed on a MACSQuant10 Flow Cytometry machine (Miltenyi).  




Raw RNA-sequencing samples in FASTQ format were downloaded from the Gene 
Expression Omnibus (GEO) database.  Mouse bone-marrow macrophages derived data data 
can be found under accession number GSE122543.  Human monocyte data can be found 
under accession number GSE60216 
 
RNA-Sequencing Analysis 
Sequencing was performed on a HiSeq 2500 High Throughput Sequencer (Illumina).  All 
previously downloaded RNA-seq samples were individually aligned using a uniform 
processing pipeline based on the STAR aligner47.  The STAR software (version 2.6.0a) was 
used in a 2-pass mode.  The first pass identifies non-annotated junctions in the input, allowing 
for the construction of a genome index containing non-annotated junctions. The second pass 
alignment is then performed against the junction-aware index.  The command line parameters 
were as follows: 
 
STAR --runThreadN 12 –genomeDir GENOME --genomeLoad NoSharedMemory --
sjdbGTFfile GTF --twopassMode Basic --readFilesIn FASTQ --outFileNamePrefix NAME -
-outSAMattributes NM --outStd BAM_Unsorted --outSAMtype BAM Unsorted --
outSAMmode Full --outSAMstrandField intronMotif --outSAMunmapped None --
outFilterType BySJout > OUTPUT.bam 
 
Following alignment, Portcullis48 was used to filter invalid splice junctions from the 
aligned BAM file.  Isoform expression was quantified using the raw fastq files and the 
mouse reference transcriptome mm9 as input for Kallisto (v.0.45.0)49.  The resultant 
normalized transcript frequencies were provided to the R package Sleuth for differential 
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analysis (v.0.30.0)50.  Alternative splicing events were detected and quantified on produced 
BAM files using the SplAdder toolkit36 as per Kahles et al., 201851.  Unproductive splicing 
events were determined using a custom Python script.  Alternative splicing sashimi plots 
across an entire gene were generated with ggsashimi52 whereby only junctions with greater 
than 5 supporting RNA-seq reads were plotted, while alternative splicing sashimi plots 
centered at an individual junction were generated with MISO25. 
 
Alternative Junction Usage Analysis 
Isoform expression was quantified using the raw fastq files and the mouse reference 
transcriptome mm9 as input for Kallisto (v.0.45.0).  Only isoforms with a TPM greater 
than 10 were considered.  Junctions from the most abundant isoform for each gene were 
selected, as long as there were 8 supporting reads for the junction.  Alternative junction 
usage was calculated by comparing the number of reads that overlap a given selected 
junction, but did not utilize the same 5’ and/or 3’ splice site, to the total number of reads 
at a junction.   
 
Quantification and Statistical Analysis 
All statistical analysis was performed in Python (version 2.7.9).  Unless otherwise indicated 
in figure legends, statistical significance measurements were marked as follows: * denotes p 
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Supplemental Figure Legends 
 
Figure S1. The Alternative 5’ Splice Site Mediating the AS Event is of Similar Strength 
to the Consensus 5’ Splice Site. (A) Histogram representing the 5’ splice site strength 
(MaxEntScore) of introns of expressed in BMDMs.  The bin with which the consensus splice 
site falls is shown by the light blue line.  The bin with which the alternative splice site falls 
is shown by the dark blue line.  (C) MaxEntScore quantifications of the consensus and 
alternative 5’ splice site. 
 
Figure S2. Oas1g Macrophage Cell Line Genotyping.  Sanger sequencing gDNA from a 
control sample (very top) and the Oas1g SS KO clones.  Sequencing is centered around the 
Oas1g alternative splice site.  Sequencing is oriented such that the negative strand runs left 
to right. 
 
Figure S3. Oas1a has a Similar Frequently Utilized AS-NMD Event.  (A) Schematic 
depiction showing the homology between Oas1a and Oas1g at the alternatively spliced third 
junction.  (B) (left) Sashimi plots centered at the third junction of Oas1g from BMDMs 
stimulated with poly(I:C) for 0, 1, 4, 8, and 12 hrs. (right) φ estimates (red line), as well as 
confidence intervals over estimates (histogram) for each time point. (C) RT-PCR upon 
stimulation with poly(I:C) confirming alternative splice site usage in control populations and 
forced productive splicing in fixed clones.  (D)  RT-qPCR analysis of Oas1g mRNA levels 
in unstimulated and stimulated (8 hrs poly(I:C)) macrophages.  Control samples are 
represented in light blue, SS KO clones are represented in dark blue.  Data is representative 
of two independent experiments (D-F) and is shown as mean (error bars indicate SEM). * 
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denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a Student’s t test.  
Results are presented relative to those of Rpl32 (D) 
 
Figure S4. Oas1a Macrophage Cell Line Genotyping.  Sanger sequencing gDNA from a 
control sample (very top) and the Oas1a SS KO clones.  Sequencing is centered around the 
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This thesis highlights the importance of post-transcriptional regulation mediated by 
mRNA splicing in the control of an inflammatory gene expression program.  In this thesis, I 
have identified unproductive splicing events that affect gene expression levels of transcripts 
involved in the innate immune response, as well as a trans-acting factor that regulates one 
such event.  This type of regulation has shown to be extraordinarily important for the fine-
tuning of the tightly regulated inflammatory gene expression program.   
While seemingly an inefficient method of regulation, post-transcriptional regulation 
is a key mechanism by which a cell can fine-tune the levels of specific transcripts.  While 
transcriptional regulation has been the focus in the study of gene expression regulation, it has 
some characteristics that make the process of fine-tuning difficult.  In contrast to post-
transcriptional regulation, transcriptional regulation is largely a cooperative venture1. It is not 
simply one protein interacting with one DNA sequence, but instead a multitude of proteins 
interacting with a host of other proteins and a variety of DNA sequences.  Thus, we believe 
that once transcriptional control has been placed on a system, changing it quantitatively is 
difficult.  In turn, secondary mechanisms, like the one highlighted in this thesis, are needed 
for the fine-tuning of gene expression levels.  While there are cellular costs due to unneeded 
transcription, we argue the fine-tuning capabilities inherent to splicing based post-
transcriptional regulation far outweigh this increased burden.  Furthermore, the very fact 
introns exist and are transient in nature argues against the idea that the cost of transcription 
is prohibitive as a significant majority of transcribed sequence are spliced and discarded2. 
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An innate immune response offers an exceptional system to study such regulation.  
The innate immune response is crucial in the fight against infection; however, there are 
inherent costs to such a response.  If this response is left unscaled or unchecked, it can do 
damage to an organism and contribute to a variety of diseases3.  Thus, this response needs to 
be highly regulated and turned on at the right scale only in response to pathogens.  If not, the 
balance can be shifted from protective to destructive immunity.  Relatively small changes to 
this tightly regulated gene expression program can have fairly drastic effects4.  Thus, this 
post-transcriptionally mediated fine-tuning is exceptionally important in such a system, and 
dysregulation has easily observable effects.  
 
Future Directions  
 
While it is apparent such post-transcriptional regulation mediated by mRNA splicing is 
frequent and wide-spread during an innate immune response, several open questions remain 
regarding the role of this form of regulation.  The most obvious questions have to do with 
the regulation of these unproductive splicing events.  With respect to the third chapter, it 
remains unknown whether or not the retention event in Irf7 is actively regulated.  We showed 
decreasing the splicing efficiency of the fourth intron has the ability to significantly dampen 
the functional output of IRF7.  We hypothesize this dampening acts to mitigate what 
otherwise might be an unchecked or inappropriately scaled response.  However, whether a 
cell actively controls this splicing event and thus the intron serves as a regulatory control 
point remains unknown.  Further, despite the fact we identified the factor BUD13 as a 
component involved with the splicing efficiency of the intron, it remains unknown whether 
BUD13 plays a role in this regulation.  An alternative hypothesis is that BUD13 simply 
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represents a mechanism that has evolved to counter IR in a subset of inherently weak introns 
that require splicing5.   
Regulation is also a question affecting Oas1g and Oas1a in the fourth chapter.  Are 
these alternative splicing events regulated by an external input or is some constant fraction 
of transcripts discarded?  With respect to Oas1g, we do notice a trend whereby increases in 
stimulation time accompany decreases in PSI (φ).  It is tempting to speculate regarding this 
trend.  For example, it is possible this unproductive splicing event acts as a break released 
upon Oas1g induction.  However, we are hesitant to draw such a conclusion without both 
increased sequencing depth at Oas1g and more sequencing time-points. Regardless, the fact 
that the alternative splice sites and much of the junction for Oas1g and Oas1a are identical 
in sequence, yet the two junction significantly differ in their usage of the unproductive splice 
site, strongly suggests a trans-acting proteins might affect this process. 
Beyond regulation, an important future direction involves the determination of 
functional relevance of many of the other identified unproductive splicing events.  While Irf7 
and Oas1g contain two of the most frequently used unproductive splicing events, they are 
not the the only events found in genes related to the innate immune response.  For example, 
in RNA-sequencing data from mouse BMDMs stimulated with poly(I:C), we found 
significantly utilized skipped exon events that led to a frameshift and incorporation of a PTC 
in the important inflammatory transcripts Mx1, IKKε, and Oasl2.  In each case, the event is 
utilized in all, or nearly all of the sequenced time-points (Chapter 4).  The computational tool 
SplAdder was used to predict and quantify AS events6.  A stringent confidence criteria was 
utilized to avoid including AS events derived from splicing noise.  However, mRNA splicing 
can be a noisy process as the dynamic nature of the spliceosome can be a source of stochastic 
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fluctuation7.  In order to prove these splicing events play a role in post-transcriptional 
regulation, and are not just a byproduct of this noise, it needs to be shown that removal of 
the event has some functional effect.   
Furthermore, little work has been done regarding the role of unproductive splicing 
during inflammation at the organismal level.  While we notice significant effects upon 
alteration of unproductive splicing events in cells grown in culture (Chapters 3 and 4), to 
gain a proper understanding of the physiological implications of the removal of such events, 
experiments need to be done at the level of an animal.  Creating a mouse lacking the 
alternative splice sites found in Oas1a and Oas1g with CRISPR-Cas9 technology should be 
relatively straightforward.  Further, it is potentially feasible to remove introns, which could 
either eliminate the potential for a skipped cassette exon or intron retention event.  Of note, 
deficiency of Bud13 has been shown to be embryonic lethal both in zebrafish8 and in C. 
elegans9, findings that are consistent with preliminary work of ours in mice.  Thus, the 
organism wide alteration of Irf7 retention through removal of Bud13 appears not to be 
feasible.  
It is important to note that all of the aforementioned work has been studied at the bulk 
level.  Cell-level insight regarding uproductive splicing could provide meaningful insight 
into the purpose and regulation of individual unproductive splicing events.  It has previously 
been reported that there is a great deal of variation in splicing patterns among single cells10,11.  
Can such heterogeneity be found among unproductive splicing events and if so, what 
regulates this heterogeneity and why does it exist?  In saying this, it remains uncertain how 
feasible it is to perform such analyses.  Innate to the sequencing of a single cell is the low 
amount of starting material, which can restrict analysis to only highly abundant transcripts12.  
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While this can be challenging in typical gene expression analyses, it is even more problematic 
when studying isoform abundance in non mutually-exclusive cases as non-dominant 
isoforms tend to be expressed at low levels and thus, are especially susceptible to “drop-
out”13.  Further, low sequence coverage common in scRNA-seq data makes it difficult to 
accurately characterize splicing variations in low abundant transcripts.  Such a problem 
might be alleviated through the development of machine learning algorithms like the recently 
published DARTS14, which offers the ability to better characterize splicing variations in 
transcripts with minimal coverage.  Technological advances in both library preparation and 
sequencing methods, as well as new computational strategies that are tailored to the 
intricacies of scRNA-seq (namely high technical noise, high processing requirements, and 
misquantification of poorly expressed isoforms due to lack of coverage) offer a great deal of 
promise15–17. 
Finally, there are potential therapeutic consequences to unproductive splicing.  This 
can be exemplified through our work with Oas1g, which shows the unproductive splicing 
event in Oas1g acts to mitigate Oas1g gene expression, and thus the antiviral response.  While 
the evolutionary history of Oas1 is quite volatile, epitomized by the fact that in humans there 
is only one copy of Oas1 that differs significantly in sequence from the eight Oas1 mouse 
paralogues, human Oas1 contains a similar unproductive splicing event.  It might be possible 
to force productive splicing of this human Oas1 transcript using an antisense oligonucleotide 
(ASO) to block the unproductive splice site.  ASOs are short, synthetic, single-stranded 
oligodeoxynucleotides that can alter RNA splicing by base pairing to cis sequences18.  The 
clinical success of drugs like Eteplirsen, an ASO which negates a frameshift mutation in 
DMD by causing the skipping of exon 51 and thus shifting the transcript back into frame, has 
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created a great deal of interest in ASOs as potential therapeutics19.  As in mice, genetic 
variation that dampens OAS1 activity has been shown to lead to susceptibility to viruses like 
West Nile virus20 and Epstein Barr virus21.  Forcing productive splicing with an ASO could 
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